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ABSTRACT
This thesis addresses the synthesis and characterization of novel inorganic silica 
nanoparticle hybrids. It focuses in large part on their potential applications in the medical 
field. Silica acts as a useful carrier for a variety of compounds and this thesis silica will 
demonstrate its use as a carrier for boron or gadolinium. Boron-10 and gadolinium-157 
have been suggested for the radiological treatment of tumor cells through the process 
called neutron capture therapy (NCT). Gadolinium is also commonly used as a Magnetic 
Resonance Imaging (MRI) contrast agent. Particles that carry it have potential theranostic 
applications of both imaging and treating tumors.
Chapter 1 presents a background on synthetic strategies and usages of silica 
nanoparticles, and NCT theory.
Chapter 2 describes a procedure to create mesoporous metal chelating silica 
nanoparticles, mDTTA. This is achieved via a co-condensation of tetraethoxysilane 
(TEOS) and 3-trimethoxysilyl-propyl diethylenetriamine (SiDETA) followed by a post­
synthesis modification step with bromoacetic acid (BrAA). These particles have a large 
surface area and well-defined pores of ~2 nm. The mDTTA nanoparticles were used to 
chelate the copper(II), cobalt(II) and gadolinium(III). The chelating of gadolinium is the 
most interesting since it can be used as a MRI contrast agent and a neutron capture 
therapeutic. The synthetic procedure developed also allows for the attachment of a
fluorophore that gives the gadolinium chelating mDTTA nanoparticles a dual imaging 
modality.
Chapter 3 presents the synthetic method used to produce two classes of large 
surface area organically modified silica (ORMOSIL) nanoparticles. Condensating the 
organosilane vinyltrimethoxysilane in a micellar solution results in nanoparticles that are 
either surface rough (raspberry-like) or mesoporous nanoparticles, which prior to this 
thesis has not been demonstrated in ORMOSIL chemistry. Furthermore, the vinyl 
functionalities are modified, using hydroboration, to make the nanoparticles into water- 
dispersible boron carriers that also have potential boron neutron capture therapy (BNCT) 
applications.
Lastly, Chapter 4 provides a general description of NCT, specifically that 
involving boron-10 and gadolinium-157. It further describes the synthetic methodology 
used in producing fatty acid coated boron nanoparticles (BNPs). The BNPs are 
encapsulated with silica to add a hydrophilic shell so that they can potentially be used in 
biological systems as BNCT agents. The silica shell is also modified with a fluorophore, 
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Theranostics is a novel approach to multifunctional agents that combine 
diagnostic (often imaging) and therapeutic (often combined with targeted delivery) 
functions in treatment of various diseases, and in particular, in the treatment of cancer. 
The combination of several modalities allows for the simultaneous imaging and treatment 
of tumors by a single construct. This design has become of particular interest with silica 
nanoparticles because of their surface modification chemistry and drug encapsulation 
properties.1
Theranostic constructs often incorporate tumor targeting ligands, groups which 
selectively and tightly bind receptors over expressed by the tumor cells (e.g. folic acid 
receptors, integrins). The attachment of a targeting ligand to the silica surface typically 
involves the use of a primary amine group (e.g. 3-aminopropyltriethoxysilane) reacting 
with the carboxylic acid group of the targeting species. For example, it has been 
demonstrated that silica modified with 3-aminopropyltriethoxysilane bound to folic acid 
has a much greater uptake into pancreatic tumor cells than silica nanoparticles that do not 
have folic acid on their surface.
There are essentially two methods in imaging inside the body, Magnetic 
Resonance Imaging (MRI) and Computed Tomography (CT). Synthesizing silica
2nanoparticles with biologically relevant imaging modality can prove difficult. The MRI 
agents gadolinium and superparamagnetic iron oxide have been the focus for introducing
2 3an imaging modality to silica nanoparticles. , In addition, nanoparticles that can 
incorporate bismuth (CT contrast agent) have recently been suggested.4
Mesoporous silica nanoparticles have been demonstrated to be useful as a drug 
delivery agent since the drug can be trapped in their pores. This process requires a release 
mechanism so that the drug can exit the pores inside the cancer cell.1 Although small 
molecule drug treatment of cancer is widely used, it is not without limitations and 
disadvantages. There is an alternative cancer treatment called Neutron Capture Therapy 
that does not require a release of drug molecules.
Multiple approaches have been proposed for the preparation of theranostic 
constructs, including liposomes,5-9 dendrimers ,10,11polymers,12-16 and nanoparticles.17-26 
Of the latter, inorganic nanoparticles in general, and silica nanoparticles in particular, are 
very attractive due to their ease of formation, diverse surface chemistry, and 
biocompatibility. The focus of this dissertation is on the preparation of internally 
functionalized silica nanoparticles for theranostic applications.
The study of inorganic nanoparticles is a burgeoning area in the field of 
nanoscience. Inorganic nanoparticles have become of particular interest for their potential
27 28 29 30use in a variety of applications, such as sensing, delivery, electronics, energy,
31 32 33 34 35imaging, therapeutics, , and separations. , Inorganic nanoparticles can be metallic, 
semiconductor, or dielectric. Metallic (i.e. gold and silver) and semiconductor (i.e. titania 
and cadmium selenide) nanoparticles demonstrate optical and electronic properties that 
are size and shape dependent.36,37 Dielectric nanoparticles (e.g. silica), although lacking
3dependent optical and electronic properties, can be synthesized in a broader range of sizes 
than other inorganic nanoparticles. Because they maintain their inert and hydrophilic 
properties, they are useful as carriers. Silica nanoparticles are especially valuable for 
many fields because they can be used as carriers of fluorescent dyes, other nanoparticles, 
various organic groups, and drug molecules.
In 1960, synthesizing silica nanoparticles involved the combustion of a silicon
38tetrachloride. The sizes of these silica nanoparticles were less than 100 nm; however, 
the resultant particles were prone to severe aggregation and size polydispersity. Werner 
Stober, Fink, and Bohn saw the necessity to synthesize uniform, nonagglomerating silica
39nanoparticles for analytical and other applications. The method developed by Stober et 
al. is still very popular, and other synthetic strategies are currently available, such as 
tailoring40-48 the aforementioned method or the use of reverse phase microemulsion.49
The inherent inertness of silica nanoparticles does not, at first, seem to offer many 
applications when compared to conductive and semiconductive nanoparticles. They have 
no optical or electronic properties, are thermally and chemically stable, and relatively 
hydrophilic. By modifying the traditional synthetic procedures, however, silica can 
become a phosphor carrier, which can improve the luminescence because its inert matrix 
prevents energy loss.50 It can also act as a nanoparticle carrier,51 imparting hydrophilic 
properties while protecting the cargo from the environment or vice versa.
Modification of the silica surface with organosilanes, utilizing surface silanols, 
can endow it with additional properties while minimizing disadvantages, thus creating an 
improved silica nanoparticle. Reactive sites for polymerization and other organic
52reactions can be achieved through the addition of organosilanes to the surface. Because
4organosilanes impart changes in hydophilicity, or charge, to the surface of these
53particles, guest species can be trapped on to the surface by noncovalent interactions, 
such as electrostatic interactions between surface and guest species. All of the endowed 
organic properties also make silica nanoparticles potentially useful in separations (i.e. 
chromatography54 and inorganic membranes55).
ORMOSILs (Organically Modified Silica) are silica nanoparticles made solely 
from organosilanes.56 Although more recently developed and less studied, ORMOSILs 
provide the same advantages as do silica nanoparticle without the necessity of post­
modifications. These particles also possess higher densities of organic functionalities 
throughout the entire particle, which makes them highly effective as guest carriers for
57 58drug delivery, and in catalysts. Additionally, their greater organic group density 
results in more groups that can be modified by traditional synthetic techniques, such as 
converting an alkene to a borate through hydroboration.
Processes that increase the surface area to volume ratio of silica nanoparticles can 
be used to increase the accessibility and/or density of silanols, or organic groups, for 
modification. This can be achieved by either making the surface-rough59 or by preparing 
mesoporous nanoparticles.60,61 This becomes important when considering silica 
nanoparticles for drug delivery,62 adsorption,63 or creating superhydrophic surfaces.64 To 
make surface-rough particles, silica nanoparticles are either co-condensed with large 
amounts of organosilanes,59 etched,64 or smaller particles are bonded to their surface.65 
For the mesoporous particle preparation, a surfactant is used to generate a micellar 
solution. The micelles in the solution act as a template around which the silica precursor 
condenses, thus creating particles with mesopores.
5Silica nanoparticles act as superb carriers for a multitude of different species, 
whether they are luminescent species within the body of the particles or another 
nanoparticle. Their applications depend on their cargo. Silica nanoparticles can be 
synthetically modified in a variety of ways to improve them as carriers. The purpose of 
this chapter is to provide a background and a history of silica nanoparticle development 
from solid spherical structures to high surface area structures, and to discuss their 
applications. The following chapters will discuss the synthesis of hybrid silica 
nanoparticles for theranostics, experiments with them, results, and conclusions of the 
studies.
1.2 Formation of Silica Nanoparticles 
Although there are many methods to synthesize silica nanoparticles,40-48 the 
typical procedures require hydrolysis and condensation steps in the presence of a catalyst 
(Scheme 1.1). Particle formation is initiated when an alkoxy silane is hydrolyzed, 
creating reactive silanols group in place of the ether. The silanols then undergo 
polymerization with other precursor units leading to dimers and oligomers, which 
supersaturate the solution and precipitate out to become distinct nuclei that grow into the 
larger silica networks. The final product of the condensation reaction can be either a 
silica gel or silica nanoparticles (Figure 1.1). 53,66
The catalyst is the controlling factor of the final product. There are two types of 
catalysts that can be used for hydrolysis/condensation, either acid (e.g. HCl) or base (i.e. 
NaOH or NH4OH). When an acid catalyst is used, creating a low pH environment, the
6hydrolysis
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53Figure 1.1: Sol-gel products resulting from different reaction conditions.
7silanols remain protonated. The lack of any significant repulsion between growing nuclei 
creates extended polymer chains that cross-link. This results in a three-dimensional gel.66 
A base catalyst produces a high pH environment that deprotonates the silanols, creating 
negative charge on the surface of the growing nuclei. The resultant electrostatic repulsion 
between the nuclei prevents the cross-linking of the silica intermediates between the
53growing particles, preventing aggregation.
1.3 Stober Method Silica Particles Synthesis 
The Stober method was first introduced in 1968 as a procedure to synthesize
39uniform silica nanoparticles. Since its inception, it is probably the most popular and 
widely developed method of silica nanoparticle preparation.
Stober et al. synthesized silica nanoparticles with the hydrolysis and condensation 
of tetraethoxy silane (TEOS) in water, ammonium hydroxide (NH4OH), and alcohol (i.e. 
methanol and ethanol) solution. When TEOS is added to the rapidly stirred solution, the 
mixture quickly becomes opaque, indicating that TEOS is being hydrolyzed and 
condensing into nuclei, which grow into distinct, monodisperse nanoparticles (Scheme 
1.2). The silica particles are collected via centrifugation and washed to remove the 
unreacted precursor and the catalyst.
Scheme 1.2: Stober method.
By controlling the environment in which the silica nanoparticle intermediates are 
made, particles with sizes ranging from 50 nm67 to 2 p,m68 in diameter can be synthesized. 
The size of the silica nanoparticles is tuned by adjusting the solution temperature,69-71
72 73NH4OH and/or alcohol concentration, or by using a different alcohol as a co-solvent. 
Increasing the temperature of the solution results in the synthesis of particles with smaller 
diameters (base on the Lifschitz-Slyozov-Wagner equation). Multiple factors such as 
surface energy, diffusion and growth rates, and equilibrium solubility are affected by
74changes in solution temperature. Increasing the concentration of NH4OH accelerates the 
rate of hydrolysis leading to more oligomer intermediates, which quickly leads to 
supersaturation, thus increasing the rate of the condensation and producing larger silica 
particles. Additionally, decreasing the polarity of the solution by increasing the alcohol 
concentration or changing the alcohol used as a co-solvent causes the silica intermediates 
to become insoluble in solution. This insolubility decreases the concentration needed for 
supersaturation and forces early nucleation. Oligomers that did not nucleate then deposit 
on the nuclei, instead of reaching supersaturation, creating larger particles.
1.4 The Use of Organosilanes for Surface Modification 
of Silica Nanoparticles
Organosilanes are one of the few chemicals that react with the inert silica
nanoparticles utilizing their surface silanols. Organosilanes are silanes that can undergo
hydrolysis and condensation to provide organic functionalities to the silica nanoparticle
surface. There are many advantages to modifying silica nanoparticles with organosilanes.
35For example, polymerization reactions or other chemical attachments (i.e. binding
75antibodies or fluorophores) can be performed. Also, polarity changes to the particles
8
9using alkyl silanes (e.g. vinyltrimethoxy silane) allow them to be dispersed in more
modification of silica nanoparticles with another hydrolysis/condensation reaction in the 
presence of the organosilane. This approach provides a defined spherical structure with a 
known surface area that has organic functionalities solely on its surface. Multiple layers 
of organic functionalities can be added because the organosilanes introduce new silanols 
during hydrolysis/condensation that can undergo further condensation. For monolayers, 
the density of the organic group on the surface is dependent on the available silanols (~2 -
3 Si-OH per nm ), but due to condensation between organosilanes, a greater surface
78coverage is often observed.
The co-condensation method involves the condensation of TEOS with the 
organosilanes, which incorporates organic groups into the silica matrix. This creates a 
higher density of available organic functionalities but may have an unwanted effect on 
nanoparticle size and shape.59,79
hydrophobic environments.76
There are two methodologies to attach organosilanes to silica, "grafting to" and
77co-condensation (Scheme 1.3). The "grafting to" approach involves the post-
Scheme 1.3: Example of "grafting to" and co-condensation products.
10
1.5 Silica Nanoparticles as Carriers of Fluorophores,
Nanoparticles, and Ions
Fluorophores are used in bioimaging or labeling, but organic fluorophores (e.g.
77FITC) are highly susceptible to photobleaching and low quantum yield, and inorganic
75 80nanoparticle fluorophores (e.g. quantum dots) are highly toxic. , Silica nanoparticles
75 77can help to ameliorate these problems. , The hydrophilic and inert nature of silica 
nanoparticles makes them useful carriers for both fluorophores and inorganic 
nanoparticles to be used in biological systems, because they can be transported to cells 
via the circulatory system without being degraded by biological catalysts. Silica, by 
encapsulating organic fluorophores, protects the dyes from photobleaching, thus 
improving fluorescence lifetime and increasing its quantum yield. For inorganic 
nanoparticles, silica creates a protective shell so that the bare inorganic particles are
sequestered from the biological environment. This prevents the inorganic nanoparticles
80from creating oxidative species or leaching toxic heavy metals.
The two typical methods to encapsulate a species within silica are the Stober
75method and reverse phase microemulsion. Encapsulating organic fluorophores using the 
Stober method is most effective when attaching the fluorophore to an organosilane and 
performing a co-condensation reaction. This allows the dye to be covalently incorporated 
on the surface and throughout the silica matrix. The dyes on the surface can be protected, 
like the core fluorophores, by adding another layer of silica around the nanoparticle post­
synthesis (Scheme 1.4).
Reverse phase microemulsion encapsulates the organic fluorophore by placing the 
TEOS and dye into the same micelle. As the TEOS condenses, the dye is passively 
trapped in the silica matrix. This process can result in dye leakage from the particle,
11
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Scheme 1.4: Generating fluorescent silica nanoparticles.
because the dye is not covalently attached (Scheme 1.4). This can be corrected by using a 
cationic fluorophore, such as ruthenium(II) chloride hexahydrate, which electrostatically 
binds to the negatively charged silica. This passive encapsulation can be also performed 
using the Stober method.
The highly fluorescent, organic dye-containing silica nanoparticles have been 
shown to be useful for biological applications. When their surfaces are modified with
targeting or recognition groups, they can provide optical differentiation of cell lines or
81 82DNA sequences. , These particles can also be used as detectors, if the fluorescence of
12
the dye is affected by the environment. This was demonstrated when detecting
nn
trinitrotoluene (TNT) with fluorescein isothiocyanate (FITC).
When encapsulating inorganic nanoparticles within silica, whether for 
fluorophores (e.g. CdSe) or for other applications (i.e. Fe2O3, Au), the same methods, 
Stober and microemulsion, can be implemented to create core-shell nanostructures
77(Scheme 1.5). The core-shell structure is a direct result of the silica not being able to 
incorporate the inorganic nanoparticle in its matrix during the condensation. 
Encapsulation involving the Stober method is used when organosilanes cannot be bonded 
to the inorganic nanoparticle. This failure results in a dependency on noncovalent 
interaction between TEOS and inorganic particles and may result in some particles not 
being encapsulated.
The encapsulation of quantum dots (QDs) by silica demonstrates a significant 
reduction, or removal, of toxic effects. Such encapsulated QDs have been used for cell 
imaging and, after modifying the silica shell, have been able to target/label different
75 77 83tumor cells. , , Furthermore, changing the cargo that silica encapsulates has given 
core-shell silica nanoparticles applications in MRI contrast when carrying
Scheme 1.5: Encapsulation of a nanoparticle using TEOS resulting in a core-shell
structure.
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superparamagnetic iron oxide and in photothermal therapy drug when gold nanoparticles 
are encapsulated.
Silica nanoparticles are not limited to encapsulation of fluorophores and other 
nanoparticles, but can also trap ions, such as heavy metal cations. The cationic metals can 
interact with the negatively charged silica surface which have proven useful as catalytic
84support. By modifying the surface of the particles with chelators, metal ions can be 
permanently trapped. Adding metal chelators to the surface has been suggested as a way
85to prepare gadolinium carriers for MRI (Scheme 1.6).
Organically modified silica (ORMOSIL) can be defined as the products of 
hydrolysis and condensation of trialkoxysilanes in the absence of a tetraalkoxy
increased density of organic groups throughout the particle. However, synthesis of 
nanoparticles from organosilanes has proven to be difficult. This limits the available 
synthetic methodologies and sometimes requires using small amounts of TEOS precursor 
to initiate particle formation.
One of the first groups to synthesize successful ORMOSIL nanoparticles was 
Ottenbrite et al.86 They used a microemulsion method with a variety of organosilanes
1.6 ORMOSIL Nanoparticles
precursor.86 This new type of silica nanoparticle is very promising, because they possess
HO,
Scheme 1.6: Representation of a metal chelating nanoparticle.
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possessing hydrophobic organic groups, which are similar to TEOS, in the presence of 
aminopropyltriethoxy silane. They demonstrated that the aminopropyltriethoxy silane 
acted more as a catalyst than a co-condensate and that the resultant 100-500  nm spherical 
particles were mainly composed of the hydrophobic organosilanes.
Buining et al. further developed the ORMOSIL synthesis. They used either an 
adapted Stober method or a micelle-mediated reaction to condense the hydrophobic 
organosilanes. To synthesize ORMOSIL nanoparticles using the Stober method, Philipse 
et al. created silica seeds using a sodium silicate solution (Scheme 1.7). The
87 88organosilanes that grew from the silica nuclei had diameters less than 200  nm. , 
Although the resulting particles consisted mostly of organosilane, they still required an 
initial co-condensation with bare silica, which made them pseudo-ORMOSILs.
Baumann et al. demonstrated that a silica seed or a co-condensate organosilane is 
not required when using a micelle-mediated synthesis. This method results in one of the 
few examples of ORMOSILs grown from a single organosilane (Scheme 1.8) .89,90 The 
micelle is produced by placing a cationic surfactant in an aqueous solution. Under the 
alkaline conditions, the micelle core creates an environment for the organosilane to 
hydrolyze/condense. The size of these ORMOSIL nanoparticles, like silica nanoparticles, 
can be adjusted by altering the concentration of the surfactant and the precursor.
Silicate solution
EtOH .  o o
--------- ** o
Si02 seed






Micelle template Internalized precursor Particle formation
Scheme 1.8: Emulsion-mediated particle growth.
ORMOSIL nanoparticles, in addition to possessing high organic group densities, 
have a more porous structure when compared to traditional silica nanoparticles. This is 
caused by the introduction of steric bulk of the organic groups, a transformation that 
disrupts the compact structure of the silica matrix. The resultant porosity is advantageous 
because it provides accessibility to the organic groups inside the particle for further 
reactions.
The porous nature of ORMOSIL nanoparticles can also allow for metal 
nanoparticle growth inside the matrix by trapping the metal growth nuclei.91 This 
prevents the agglomeration-prone metallic particles from aggregating. The metal 
nanoparticle is then able to impart its functionalities, such as catalytic, fluorescent, or 
photothermal therapeutic properties, to the overall structure.
1.7 Surface-rough Silica Nanoparticles
The density of silanols on spherical silica nanoparticles, and thus organic 
functionalities, is limited by the available surface area. The surface area can be increased 
by increasing the sphere size, but the size of the particle can only be increased to a few 
hundred nanometers. Surface area can also be increased by synthesizing nanoparticles 
that are not smooth, but surface-rough.
16
Surface-rough nanoparticles, also referred to as raspberry nanoparticles, possess a 
larger surface area compared to traditional silica nanoparticles by at least a factor of 2 .59 
There are two common methods to produce these types of particles (Scheme 1.9). The 
first method involves modifying a larger silica particle with smaller silica particles.65,92 
This can be done by attaching aminopropyltriethoxy silane to the surface of the larger 
particle and then mixing the aminated silica with the smaller, negatively charged silica 
nanoparticles that bind electrostatically the positively charged aminated particles. The 
resultant particle has a larger surface area compared to the smooth particles of the same 
size; however, these particles are often large, with diameters in the micron range.
The other method for creating surface-rough nanoparticles involves etching of 
silica nanoparticles with a reducing agent, such as sodium borohydride.64 This has little 
effect on the size, but leads to more available surface silanols. The new surface-rough 






Scheme 1.9: Representation of synthetic strategies to make surface-rough nanoparticles.
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Surface-rough silica nanoparticles are of particular interest for the development of 
antifogging, water-repellent glass chromatographic separations.65,93,94 To give glass this 
modality, it has to be processed with an organosilane, typically aminopropyltriethoxy 
silane, enabling it to bind electro-statically to the nanoparticles prior to any modification 
step. The hydrophobicity of these particles is attributed to the rough surface and not the 
hydrophobic groups attached to them.
1.8 Mesoporous Silica Nanoparticles
In 1992, mesoporous silica nanoparticles were developed at Mobil Corporation 
laboratories.95 These particles have well-defined mesopores and increased surface area. 
Mesoporous silica nanoparticles have attracted attention as a highly porous molecular 
sieves95 and a drug carrier.96
Mesoporous silica is synthesized by the hydrolysis and condensation of a silica 
precursor (e.g. TEOS) in a micellar solution (Scheme 1.10). The micelles act as a 
template around which the silica precursor polymerizes. The micelles are removed from
97the final product by calcination or by solvent leaving a porous structure. The 
mesoporous structure can be synthesized with different pore diameters, varying degrees 
of pore penetration, and ordered or disordered porous networks by using a diverse array 
of surfactants.
The late Victor Lin made a major contribution to the development of mesoporous 
silica nanoparticles. His group prepared mesoporous silica particles that are 
monodisperse and possess uniformly high levels of porosity. This was done by 




Scheme 1.10: Generation of mesoporous silica from micellar template.
cationic surfactant, and the anionic silica intermediates.98 Additionally, organosilanes 
were introduced into these highly porous particles imparting organic functionalities.
When modifying mesoporous silica particles, the same two methods can be 
applied as with standard silica nanoparticles. The "grafting to" approach provides a well- 
defined scaffold to modify. However, due to the silanol distribution, there is an uneven 
distribution of organic groups observed and modifications tends to cause pore blocking.99 
On the other hand, using co-condensation results in even organic group distribution 
without pore blocking, but increasing the organosilane concentration leads to the loss of 
mesoporous structure (Scheme 1.11) .100
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Scheme 1.11: Representation of "grafting to" mesopores and co-condensation.
Applications for mesoporous silica nanoparticles commonly revolve around drug 
delivery. Because of their porous channels, they can easily uptake and release molecules. 
Uptake is accomplished by immersing the particles in the cargo molecule solution.101,102 
The molecule can then be trapped by sealing the ends of the pores with either a cleavable 
plug103 or environment-responsive polymer (Scheme 1.12) .104 For example, an 
anticancer drug, DOX, can be loaded into the mesoporous silica and trapped by coating 
the particle with a polymer containing a disulfide bond.104 When the particle enters the 
cell, the antioxidant glutathione cleaves the disulfide bond causing the ejection of the 
polymer from the surface, thus unblocking the pores and causing DOX to be released
inside the cell. 104
20
Scheme 1.12: Mesoporous nanoparticle molecule loading and trapping.
1.9 Neutron Capture Therapy 
In the United States alone, there are about eleven million people with some form 
of cancer.105 Since the 1970s, the United States, through the National Cancer Institute 
(NCI), has put more than two hundred billion dollars into finding treatments and cures for 
cancer.106 Presently, treatments are limited to chemotherapy, surgery, radiation therapy, 
and interferon therapy. The problem with current methods is that none are localized to the 
tumor itself; even surgery requires damaging healthy tissue. This reduces their 
effectiveness and increases treatment complications. In 1936, George Locher proposed as 
a possible solution using boron as a localized cancer therapeutic. His idea is now known
107as boron neutron capture therapy (BNCT).
Neutron capture therapy is based on the adsorption of slow neutrons in the nuclei 
of a nonradioactive isotope located inside, or adjacent to, the tumor cell. The adsorption 
of the neutrons leads to the release of radiation in the form of high linear energy transfer 
(LET) particles damaging the target cell. In addition to being nonradioactive, the isotope 
has to have a capture cross-section that is many times greater than that of elements 
typically found in tissues (Table 1.1) so that the neutrons are absorbed by the therapeutic 
isotope. A list of capture cross-sections can be seen in Table 1.2. 10B (BNCT) is the most
21
Table 1.1: Thermal Neutron Capture Cross-Section Values of Tissue 















H 0.332 10.00 P 0.18 1.16
C 0.0034 18.0 S 0.53 0.20
N 1.82 3.0 Cl 32.68 0.16
O 1.8 x 10-4 65.0 K 2.1 0.20
Na 0.43 0.11 Ca 0.4 2.01
Mg 0.053 0.04 Fe 2.57 0.01






6Li 942 151Eu 5800
10B 3838 155Gd 61000
22Naa 32000 157Gd 255000
58Coa 1900 164Dy 1800
113Co 19800 184Os 3000
126 ja 6000 199Hg 2000
135Xea 2600000 230Paa 1500
148mPma
149n
10600 235^ ja 
241^  a
580
Sm 42000 241Pua 1010
a: Radioactive
popular isotope due to its low toxicity and chemistry that allows for easy incorporation
157into a variety of small and macromolecules. Gd (GdNCT) is the only other proposed 
potential neutron capture therapeutic because it is nonradioactive and it has the second 
highest capture cross-section of all elements. The challenges with GdNCT are that 
gadolinium is toxic and therefore must be tightly bound to the carrier, it has to be located
closer to the nucleus to maximize LET damage, and the y rays it produces are not
108localized to the target cell.
BNCT is the process in which boron-10 undergoes nuclear fission through an 
alpha decay pathway by absorbing a thermal neutron (0.025 eV). The fission reaction 
produces two high LET products, an alpha particle (1.47 MeV) and 7Li (0.84 MeV). The 
maximum travel range that these high LET products in tissue is 9 |im .107,109 Since a 
typical human cell is 10-30 |im ,110 the radiation is mainly localized to cells containing 
10B, with some possible damage done to immediately adjacent cells.
Although localized treatment is important, there are two requirements that any 
boron compound must meet to be a plausible BNCT agent. First, the minimum amount of 
10B must be ~109 atoms per cell to provide a greater chance for neutron capture, and 
second, the tumor-to-normal tissue and tumor-to-blood boron concentration must be 
greater than 3:1, so as to localize the BNCT reaction to the tumor without doing 
irreparable damage to the normal tissues.107,111-114
There are two boron compounds that have been clinically studied as BNCT 
agents, mercapto-undecahydro-closo-dodecaborate (BSH) and p-boronophenylalanine 
(BPA) .107,115,116 In animal testing studies, BSH has a tumor-to-blood ratio of 1.3:1, which 
is much less than the required ratio. It has been suggested that the tumor-to-tissue ratio is 
more important than the tumor-to-blood ratio; therefore, if that ratio is increased, the 
BSH is still a good treatment candidate. BPA meets both requirements. It is, however, 
selective only to gliomas and melanomas. According to clinical studies of BPA, a
117minimum dosage of 250 mg/kg body weight is needed to be effective, because only 1 
out of every 5 BPA molecules (20% 10B) could undergo neutron capture. Besides BPA
118 119 120 121 122and BSH, boronporphyrins, , amino acids, polyhedral boranes, , boronated
123 124 125anti-epidermal growth factor receptor, DNA-binding agents, , and monoclonal
22
antibodies126 have been proposed as alternative boron delivery agents. Presently, 
increasing the 10B capacity to improve the chance of neutron capture has become a focus 
for modern BNCT agent preparation.
1.10 Thesis Overview 
It is the goal of this thesis to describe the development of theranostic silica 
nanoparticles. We report synthetic methodologies that lead to gadolinium-containing 
mesoporous silica nanoparticles and boron-containing silica nanoparticles. It describes 
metal-sequestering with silica nanoparticles via organic group modification so that they 
can chelate gadolinium giving them potential imaging and therapeutic applications, novel 
mesoporous and surface-rough ORMOSIL nanoparticles, that can be modified to contain 
large amounts of boron for BNCT, and surface modification of boron nanoparticles with 
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CHAPTER 2
MESOPOROUS METAL-CHELATING SILICA NANOPARTICLES
2.1 Introduction
Nanoparticles that can bind metals have potential applications in medical
treatment for diseases that involve the buildup of metals in the body, such as Alzheimer's
1 2 and Parkinson's disease,1 in metal sequestering for water treatment,2 fluorescent
enhancement,3,4 and as carriers for MRI contrasting agents.4-6 Most of these metal-
2 4 5 8binding nanoparticles utilize thiols or polyamino carboxylic acids to chelate metals. , , , 
Silica nanoparticles, because of their uniform sizes, inert nature, and low toxicity may act 
as useful supports for metal chelator functionalities.
Recently, many metal-chelating nanoparticles have been synthesized using thiol,
3 8 9or amino-containing silanes. , , In the case of amino-containing silanes, a second step is 
required to convert them to polyamino carboxylic acid functionalities. The number of 
organic functionalities on the silica nanoparticle is dependent on the available silanols on 
its surface. Potentially larger amounts of metals can be chelated if the number of the 
silica nanoparticle's available organic groups are increased. This can be accomplished by 
increasing the surface area of the silica nanoparticle.
Silica particle surface area can be increased by creating channels (2-50 nm in 
diameter) in the silica nanoparticle.10 This results in mesoporous silica nanoparticles 
(MSNs) that have a larger surface area while maintaining the same particle volume,
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compared to nonporous silica particles of identical size. MSNs can thus provide more 
available silanols for organosilane modification.
There are two main methodologies in attaching an organosilane to the surface of 
MSNs. The "grafting to" approach provides a well-defined structure (e.g. MCM-41), but 
can give a nonuniform distribution of the organosilane and potentially block the pores.11 
The other method involves the co-condensation of both the organosilane and the 
tetraalkoxy silane, e.g. TEOS (Scheme 2.1). This "one-pot" synthesis provides a uniform 
distribution of the organosilane with no pore blocking. However, the higher the
12concentration of the organosilane used the more the mesoporous structure degrades.
Recently, it has been demonstrated that nanoparticles with large gadolinium 
loading have greater r1 and r2 relaxivities compared to single-molecule gadolinium 
carriers for MRI applications.4,6 ,13,14 The synthesis of these gadolinium-containing 
nanoparticles involves the treatment of 3-trimethoxysilylpropyl diethylenetriamine
1. H20 , CTAB, EG, NH4OH, 343 K
OMe
2. TEOS, stir 24 hrs, 343 K
3. EtOH, stir 48 hrs, 343 K
Nl-(3-Trimethoxysilylpropyl)diethylenetriamine (DETA)
Scheme 2.1: Co-condensation of SiDETA with TEOS in CTAB solution resulting 
in mesoporous nanoparticles.
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(SiDETA) with bromoacetic acid under basic conditions (Scheme 2.2) to create a 
polyaminocarboxylic acid containing silane, diethylenetriametetraacetic acid (SiDTTA). 
Typically, gadolinium ions are then chelated by the resultant SiDTTA prior to modifying 
the surface of the solid silica or mesoporous silica nanoparticles. These methods may 
hinder access to gadolinium by creating multilayers (post-modification of solid silica), 
blocking the pores (post-modification of MSNs), or incorporating SiDTTA-Gd within the 
MSN matrix and not on the surface (co-condensation of SiDTTA-Gd with TEOS). The 
potential inaccessibility of gadolinium, specifically to water, can greatly reduce the 
effectiveness of these particles as MRI contrast agents.
Additionally, gadolinium has a potential use in neutron capture therapy of cancer,
157as mentioned in Chapter 1. Gd has been suggested as a neutron capture therapeutic 
because of its large neutron capture cross-section, which reduces the amount of 
gadolinium needed to be an effective NCT agent.15 A nanoparticle that contains 
gadolinium, therefore, can potentially image and treat tumor cells simultaneously. The 
only theranostic aspect that these "as is" particles lack is cell targeting which can easily
3-aminopropyl(trimethoxysilyl)diethylenetriamine tetraacetic acid (SiDTTA)
Scheme 2.2: Conversion of DETA to DTTA using bromoacetic acid under basic 
conditions.
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be added by modifying the silica surface with an organosilane (e.g. 3-aminopropyl- 
triethoxysilane) that can be attached to a targeting ligand.
This chapter presents a synthetic method to create mesoporous silica 
nanoparticles that contain the polyamino carboxylic acid DTTA. This is achieved by co­
condensation of TEOS and DETA followed by treating the particles with bromoacetic 
acid at pH 8 . This opens up the possibility of using these nanoparticles to chelate a 
variety of metals, thus creating potential applications in metal sequestering and neutron 
cancer therapy. Additionally, because gadolinium is chelated post-synthesis, the 
gadolinium ions are chelated by accessible DTTA molecules only. This should result in 




Tetraethoxy siliane (TEOS, Alfa Aesar), 3-trimethoxysilylpropyl 
dietheylenetriamine (SiDETA, Sigma-Alrich), Bromoacetic acid (BrAA, Sigma Aldrich), 
Ammonium hydroxide (NH4OH), Hexadecyltrimethylammonium bromide (CTAB, 
Sigma Aldrich), Ethylene glycol (EG), 200 proof ethanol, MilliQ water, Dibasic sodium 
phosphate (Na2HPO4), Monobasic sodium phosphate (NaH2PO4, Mallinckrodt), 
Disodium ethylenetriaminetetraacetic acid dihydrate (Na2EDTA2H2O, Mallinckrodt), 
Calcium chloride anhydrous (CaCl2, Mallinckrodt ), Cupric chloride dihydrate 
(CuCl2 2H2O, J.T. Baker), Cobalt chloride (CoCl2, Sigma-Aldrich 97%), Gadolinium 
chloride hexahydrate (GdCl3 6H2O, Sigma-Aldrich), Murexide (Sigma-Aldrich), and 
Eriochrome Black T (Mallinckrodt).
2.2.2 Instruments
Transmission electron microscopy (TEM, FEI Techna G2 T-12), 
Thermogravimetric analysis (TGA, TA Instruments 2950 Thermogravimetric Analyzer), 
Infrared spectroscopy (IR, Bruker Tensor 37), Dynamic light scattering (DLS, NICOMP 
380 ZLS), and Nitrogen adsorption-desorption (BET analysis, Micrometrics ASAP 
2 0 2 0 ).
2.2.3 Co-condensation of SiDETA and TEOS
90 mL MilliQ water, 0.5868 g CTAB, 15 mL EG, and 3.6 mL 25% NH4OH are 
added to a 250 mL round bottom flask and stirred at 70 °C. After 25 minutes, 207 |iL of 
SiDETA and 715 ^L TEOS are added to the solution (32% w/w) followed by the addition 
of 43 mL ethanol after 24 hours. The solution is stirred for an additional 48 hours to 
ensure complete mesoporous nanoparticle formation and maximum incorporation of 
SiDETA. The particles are collected by centrifugation and washed 3 times with ethanol. 
The CTAB is removed from the pores by transferring the mesoporous DETA 
nanoparticles to a 100 mL round bottom flask containing 30 mL of a 1 M HCl ethanol 
solution, heated to 80 °C, and allowing it to sit for 14 hours. The particles are then 
collected and washed 3 times with ethanol to remove the free CTAB and HCl (Scheme 
3.1).
2.2.4 Conversion of DETA mesoporous silica nanoparticles 
to DTTA mesoporous silica nanoparticles
A 6:1 mole ratio of BrAA and DETA are added to a 25 mL round bottom flask.
10 mL of a 0.1 M phosphate buffer (pH 8) are added to the flask followed by the
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dropwise addition of 1M NaOH until the solution reaches a pH of 8 . The solution is then 
stirred and heated to 80 °C for 2 hours. The DTTA containing mesoporous silica 
nanoparticles are then collected via centrifugation and washed 3  times with water to 
remove any excess BrAA. The particles are then dried under air (Scheme 3.2).
2.2.5 Calcium solution
A 0.04 M calcium standard is made by adding 1.1098 g CaCl2 (0.01 mol) to a 150 
mL beaker. 25 mL MilliQ water is added to the beaker. Then concentrated HCl is added 
to the beaker until the CaCl2 solid is dissolved. Two additional drops concentrated HCl 
are added to the solution. The solution is then transferred to a 250 mL volumetric flask 
that is filled with MilliQ water.
2.2.6 Phosphate buffer solution
A 0.1 M phosphate buffer is made by adding 12.6931 g Na2HPO4 and 0.3657 g 
NaH2PO4 to a 250 mL volumetric flask and filled with MilliQ water. The pH of the 
solution is the adjusted to 8 if needed. This solution is used to maintain the solution pH 
for DETA to DTTA conversion and for copper(II) and cobalt(II) titrations.
2.2.7 EDTA standard solution
3.8 g of Na2EDTA2H2O (10.21 mmol) and 0.1 g of MgCl2 are added to a 1 L 
volumetric flask. The flask is filled with MilliQ water (if the solution stays murky, 1 M 
NaOH is added dropwise before water is filled to mark). The solution is then filtered
using Buchner funnel and vacuum. The stock solution is standardized by titrating the
2+
Ca solution with Eriochrome Black T. The stock solution should be about 0.01 M. A 
100 mL aliquot of the EDTA stock solution is then placed in a clean 1 L volumetric flask
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and diluted with MilliQ water adjusting the pH to 8 , and standardized by titrating Ca . 
This solution is used for testing the metal chelation of the nanoparticles.
2.2.8 Copper solution
A 0.04 M copper(II) solution is made by adding 1.7048 g CuCl2 2H2O (0.01 mol) 
to a 250 mL volumetric flask. The flask is filled with water but not to the marker. 
Ammonia is added dropwise to the solution as an auxiliary complexing agent until the 
royal blue color persists. The solution is then adjusted to pH 8 and water added to the 
marker. Aliquots of the solution are then added to flasks containing 7 mL pH 8 phosphate 
buffer. 2 drops of Murexide indicator (1 mg Murexide per mL H2O) are added to each 
flask and the contents standardized with EDTA solution.
2.2.9 Cobalt solution
A 0.04 M cobalt(II) solution is made by adding 1.2984 g CoCl2 (0.01 mol) to a 
250 mL volumetric flask. The flask is filled with water but not to the marker. Ammonia is 
added dropwise to the solution as an auxiliary complexing agent until a darkish pink is 
observed. The solution is then adjusted to pH 8 and water added to the marker. Aliquots 
of the solution are then added to flasks containing 7 mL pH 8 phosphate buffer. 2 drops 
of Murexide indicator (1 mg Murexide per mL H2O) are added to each flask and the 
contents standardized with EDTA solution.
2.2.10 Gadolinium solution
A 0.04 M gadolinium(III) solution is made by adding 3.717 g GdCl3 6H2O (0.01 




adjusted to pH 7. This solution is used for TGA measurements and not for titration so it is 
not standardized.
2.2.11 Copper and cobalt chelation
A known mass of the DTTA-containing nanoparticles (5-20 mg) is added to a 
flask. Then an excess of copper or cobalt solution (0.25-0.75 mL) is added followed by 
the addition of 7 mL phosphate buffer. The solution is sonicated for 30 minutes and 
allowed to sit for 1.5 hours. 2 drops of Murexide solution are added to the solution 
immediately followed by EDTA titration. The difference between the initial moles of the 
metal ion and moles of EDTA used results in the moles being chelated by the DTTA.
2.2.12 Gadolinium chelation
100 mg of DTTA-containing nanoparticles are added to 6 mL of gadolinium 
solution and sonicated for 2 hours. The particles are then collected via centrifugation and 
washed 3 times with EDTA solution to remove free or loosely bound metal. The particles 
are then washed 3 times with water to remove EDTA and dried.
2.2.13 Fluorescent tag addition
Dansyl chloride is used as the fluorescent tag, because it reacts quickly with 
primary amines. 4 mg of dansyl chloride in 5 mL dry acetonitrile is added to the DTTA- 
containing nanoparticles and gadolinium chelating nanoparticles. The particles are 
washed with acetonitrile until the supernatant no longer fluoresces. A UV lamp is used to 
observe fluorescence.
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2.3 Results and Discussion 
A co-condensation method was implemented in the synthesis of DETA- 
containing mesoporous silica nanoparticles. This approach was expected to prevent any 
pore blockage and also produce a more homogeneous distribution of organic
19functionalities. Figure 2.1 shows the particles obtained using a 32% w/w of SiDETA to 
TEOS in the presence of the surfactant CTAB. These mesoporous DETA-containing 
silica nanoparticles (DETA-MSNPs) are uniform in size (111±4 nm) and have mesopores 
easily observed by TEM (Figure 2.1). Using nitrogen isotherm analysis (Figure 2.2a), a 
type IV isotherm with a hysteresis loop was observed for DETA-MSNPs, which is 
representative for mesoporous structures (Figure 2.3a) .16 The measured pore size of these 
mesoporous particles, based on the isotherm data, is 2.6 nm (Figure 2.3b). The particles
Figure 2.1: TEM image of DETA-MSNPs.
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Relative pressure--------►
Figure 2.2: Representations of adsorption-desorption isotherms and hysteresis 
loops. a) Types of isotherms (type IV and type V are considered isotherms 
for mesoporous materials) b) Types of hysteresis loops.16
2
have a calculated surface area of 664 m /g, which is much larger than the solid spherical 
silica nanoparticles’ (~200 nm) surface area (17 m /g). After the conversion of DETA to 
DTTA to make DTTA-containing mesoporous silica particles (DTTA-MSNPs), the same 
type IV isotherm was observed with pore sizes of 2.2 nm (Figures 2.4a-b). However, the 
surface area decreased to 572 m /g. We speculate that this decrease is caused by some 
pore blockage. The average diameter of DTTA-MSNPs remained virtually unchanged at
108 ± 4 nm (Figure 2.5), compared to DETA-MSNPs.
The conversion of DETA to DTTA was confirmed using IR spectroscopy (Figure 
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Figure 2.3: Nitrogen adsorption-desorption analysis of DETA-MSNPs. a) Nitrogen 
adsorption-desorption isotherm of DETA-MSNPs. b) Pore size distribution for 











Figure 2.4: Nitrogen adsorption-desorption analysis of DETA-MSNPs. a) Nitrogen 
adsorption-desorption isotherm of DTTA-MSNPs. b) Pore size distribution for 





Figure 2.6: IR spectra of DETA-MSNPs (black) and DTTA-MSNPs (red).
and silanol O-H stretches. After DETA is converted into DTTA, two intense peaks are 
observed at about 1650 cm-1, representing the C=O stretch, and at 1380 cm-1, which is 
probably a combination of O-H bends and C-O stretching. There is also a distinct 
broadening of the 3400 cm-1 peak for the DTTA-MSNPs caused by the presence of O-H 
stretching from the carboxylic acid.
Another indication that the DETA-MSNPs have being converted to DTTA- 
MSNPs is that their zeta potentials are different. The zeta potential for DETA-MSNPs is 
+53.1 mV but after DETA conversion to DTTA, a negative potential of -29.3 mV is 
observed.
Using TGA, a weight loss of the DETA-MSNPs organic groups was observed 
between 300 and 800 °C, with the loss of 11.12 % (Figure 2.7). It should be noted that 
TGA plots for DETA-MSNPs contain a weight loss that is greater than DTTA-MSNPs, 
which is the opposite of what is expected since the DTTA-MSNPs have a greater organic 
molecular weight. This can be attributed to the combustion of CTAB that is remaining 
with the DETA-MSNP sample. This theory is supported by the stepwise weight loss at 
300-375 °C disappearing during DTTA-MSNP analysis which is believed to happen 
because of the additional washing steps removing the remnant CTAB. Although the
CTAB may prevent some DETA from being converted to DTTA, it may also 
preserve some advantageous primary amines, as will be discussed below.
After converting DETA to DTTA, a weight loss of 17.66 % was observed (Figure 
2.7). From these data, the conversion of DETA to DTTA inside the mesoporous silica 
particles is approximately 22.8% (Eq. 2.1-2.3). The low conversion of the total DETA 




Figure 2.7: TGA weight losses of DETA-MSNPs (black) and DTTA-MSNPs (red).
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Eq. 2.1: Determining the moles DETA per particle based on TGA weight loss: p is the 
particle density in g-cm- (~1.46), r is the particle radius, M W De t A is the molecular 
weight of DETA, and %Wloss is the measured weight loss of the DETA-MSNPs 
according to TGA.
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Eq. 2.2: Determining the moles DTTA per particle based on TGA data: p is the 
particle density in g-cm- (~1.46), r is the particle radius, MWDTTA is the molecular 
weight of DTTA, and %Wloss is the measured weight loss of the mesoporous 
nanoparticle according to TGA.
m o l D T T A  m o l D E T A
---------- ------ :-------------—  X  10 0  =  m o l %  D E T A  co n v e rs io n
p a rt ic le  p a rt ic le
Eq. 2.3: Determining the percentage of moles DETA converted to moles DTTA.
inside the silica nanoparticles, in addition to being incorporated onto the surface, during 
co-condensation.6 This is supported by calculating the number of DETA functionalities of 
the mesoporous nanoparticle surface using the measured surface area (664 m /g). By 
assuming a DETA surface coverage of 1 molecule DETA per nm2, the total percentage of 
DETA on the surface is determined to be ~16% of the total DETA functionalities 
throughout the silica nanoparticle body. This indicates that all surface DETA 
functionalities are being converted into DTTA functionalities and that the CTAB 
remaining with the DETA-MSNPs is not preventing conversion inside the pores.
Next, we studied the metal chelation (Cu2+, Co2+, and Gd3+) by DTTA-MSNPs.
2+ 2+
We used EDTA titration with a Murexide indicator for Cu and Co solutions before 
and after the chelation with the nanoparticles to determine the extent of the metal uptake. 
Because DTTA binds metal cations more strongly than EDTA, while DETA groups do 
not, it may be possible to determine the extent of DETA to DTTA conversion using 
EDTA titration. This was observed when titrating DETA-MSNPs and DTTA-MSNPs 
treated with the copper(II) solution. The number of moles EDTA used for the titration of 
copper(II) in the presence of DETA-MSNPs was equal to the starting moles of copper(II) 
(this is also observed by the loss of blue color from the particles). However, during the 
titration copper(II) in the presence of DTTA-MSNPs, fewer moles of EDTA were used to 
complete titration, indicating that the number of DTTA groups may be equivalent to the 
untitrated moles of copper(II). Furthermore, an additional correction is made for the 
initial weight of DTTA-MSNPs titrated by calculating the theoretical weight percentage 
of DTTA functionalities in a particle (Eq. 2.4-2.6; 63.6%) and multiplying that value to
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the weight of the particles titrated to get a theoretical maximum value of moles DTTA 
present in a given sample.
% W siDEXA H- M W siDEXA • M W s i 0 l 5 DETA
— /o W Sio 1 5 DETA
% W SiDETA H- M W SiDETA • M W Sio 1 5 DETA +  % W j Eo s  M W TEOs • M W Sio ;2
Eq. 2.4: Determining the percent weight composition of SiO15DETA in a particle 
sample: %WSiDETA is the percent of the organosilane used (32%).
________________ %wsi0i 5DETA _  n /™  1
5 Z w  / o l w  / — /0m o ls iO 15DETA
M W ( /0  WS 1 0  !■ 5 D E TA/  4- /0  WS 1 0  /   ^ 'M Wsi0^ 5Deta ( /  MWs 1 0  , ■ 5D eta 4  / MWs ; o J
Eq. 2.5: Theoretical mol percentage of DETA in a particle sample.
% m o l s i o 1 5 D E T A  ‘ MWdxxa
% m o l s i o 1 5 D E T A  ‘ MWsi0l 5 D T T A  + (100 — % m o l s i 0 i  5deta) • MWsio.
— %WDTTA
Eq. 2.6: Theoretical weight composition of DTTA of the particles if all DETA groups 
are converted to DTTA.
The EDTA titration data for Cu2+ and Co2+ are shown in Figures 2.8 and 2.9, 
respectively. The slopes of the two lines represent the mole percent of the metal chelated 
by the DTTA-MSNPs, 16.9 ± 1% for Cu2+ and 19.7 ± 2% for Co2+. These mole percents 
correspond closely with the calculated 22.8% DETA/DTTA conversion value from the 
TGA data and the theoretical surface coverage of DETA (~16%), supporting the theory 
that EDTA titration can be used to determine the percentage of DETA converted. By 
accounting for the 22.8% in the titration data, instead of the theoretical weight percent, 
we conclude that ~50-60% of the DTTA participate in metal chelating. This implies that 
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Figure 2.8: Moles of copper chelated by DTTA-MSNPs. With a slope that 
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Figure 2.9: Mole of cobalt chelated by DTTA-MSNPs. With a slope that 
represents the moles of DETA converted.
3+Gd is difficult to titrate because it precipitates during the titration with the 
alkaline EDTA solution. Thus, we used TGA to determine the percentage of Gd3+ that is 
chelated by the DTTA-MSNPs. Samples were prepared by soaking the DTTA-MSNPs in
3+a solution containing large excess of Gd . The particles were then collected by 
centrifugation and washed twice with EDTA solution then twice with water. TGA 
analysis of the dried particles gave weight losses of 17.7 and 16.4% for DTTA-MSNPs 
and DTTA-MSNPs-Gd, respectively (Figure 2.10). This means that a 1.3% weight of
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Figure 2.10: TGA weight losses of DTTA-MSNPs(red) and DTTA-MSNPs-Gd 
(blue).
gadolinium is being chelated (~45% of available DTTA molecules chelating Gd), which
19 3corresponds to a gadolinium loading of ~7.1 x 10 Gd atoms/cm using Eq. 2.7-2.8.
13For comparison, Rieter et al. prepared solid silica nanoparticles coated with
SiDTTA-Gd with an average diameter of 37 nm containing 2.4 x 1020 Gd/cm3. Taylor et
al.6 synthesized mesoporous Gd-containing silica particles (T-mDTTA-Gd), with an
average diameter of 75 nm, and surface area approximately 5 times higher than that of
our DTTA-MSNPs. They grafted SiDTTA-Gd to mesoporous silica and obtained a 
maximum gadolinium loading of 3.3 x 1020 Gd/cm3. Although the T-mDTTA-Gd
9
particles had a much larger surface area (1470 m /g), the "grafting to" approach reduced 
their pore size from 2.4 nm for the starting mesoporous silica to 0.9-1 nm for T-mDTTA- 
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Eq. 2.7: Mass of a single DTTA-MSNP.
%WGd • WSp • Na atoms Gd 
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Eq. 2.8: Number of gadolinium atoms per particle volume based on TGA 
data.
Furthermore, designs for gadolinium-carrying particles usually involve the 
incorporation of a fluorophore to give the particle a dual imaging modality. This typically 
requires another silane, commonly APTES, for fluorophore attachment. With our DTTA- 
MSNPs, there are free primary amines from the unreacted DETA molecules. To confirm 
their presence, we treated DTTA-MSNPs with dansyl chloride. Figure 2.11 shows the 
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Figure 2.11: Fluorescence of dansyl chloride modified DTTA-MSNPs-Gd 
(Left) and DTTA-MSNPs (Center). To the right is a solution of dansyl 
chloride in acetonitrile with no amines present.
2.4 Conclusions
A new procedure to synthesize mesoporous metal-chelating silica nanoparticles 
has been developed. These nanoparticles are prepared by co-condensation of TEOS and 
diethylenetriametetraacetic acid under basic conditions in the presence of CTAB, 
followed by the conversion of DETA to DTTA. These particles maintain the large surface 
area after the DETA conversion and keep their pore sizes in the mesoporous range, which 
is not typically observed for "grafted to" mesoporous analogs. These particles can chelate 
a variety of metals, such as gadolinium, copper, and cobalt, giving them potential 
applications in a variety of fields, such as MRI, neutron capture therapy, and metal 
sequestering.
Despite the fact that other silica nanoparticles using chelation to bind gadolinium 
have been suggested as MRI contrast agents, our new synthetic strategy has the potential 
to maximize gadolinium access to water by maintaining mesopore diameters and 
chelating gadolinium to exposed DTTA functionalities, while providing an additional 
organic handle for fluorescent tag attachment to impart dual imaging modality.
Moreover, DTTA-MSNPs can act as theranostic agents with MRI diagnostic and neutron 
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CHAPTER 3
THE SYNTHESIS OF LARGE SURFACE AREA VINYL ORMOSIL
NANOPARTICLES
3.1 Introduction
The chemical and thermal stability and hydrophilic properties of silica 
nanoparticles make them useful carriers for fluorophores and other inorganic 
nanoparticles. These silica nanoparticle carriers have potential applications in the fields 
of optics, imaging, and therapeutics.1 Although silica is relatively inert, when modified 
with organosilanes, silica nanoparticles gain advantageous organic functionalities. For 
example, organosilanes can change the surface charge or polarity of the silica 
nanoparticles, and/or can be further modified by traditional synthetic techniques.
Silica nanoparticles can be modified with an organosilane by "grafting to" or co­
condensation methods.1 The "grafting to" approach adds organic functionalities to the 
surface of an already synthesized silica nanoparticle. When dealing with a monolayer, the 
organosilane surface coverage becomes highly dependent on the surface silanols of the 
particle and steric interactions between organic functionalities. When a multilayer is 
formed by the condensation of the organosilane with itself, the number of organic groups 
increases, but so does the size of the particle. Additionally, the multilayer may prevent 
access to organic functionalities located closer to the core of the particle.
The co-condensation approach provides organic functionalities throughout the 
silica nanoparticle body. Although this method results in a greater number of organic 
functionalities, the core groups are relatively inaccessible for further modification and 
typically need to be modified prior to co-condensation (e.g. covalent encapsulation of a 
fluorophore). For both methods, the accessibility and apparent number of organic 
functionalities is mostly limited to those on the silica surface.
Recently, methods that increase the surface area to volume ratio of silica 
nanoparticles and thus increase the number and/or accessibility of the organic 
functionalities have been developed. These methods involve the synthesis of surface- 
rough3 or mesoporous structures.4 Even though both structures have a greater surface area 
than solid silica nanoparticles, their applications are very different.
Surface-rough silica nanoparticles are synthesized by etching the silica particles5 
or by adding smaller silica spheres to the surface of a larger silica spheres. When 
modified with hydrophobic organosilanes, these surface-rough silica nanoparticles 
possess superhydrophobic properties and have been used in producing water-repellent 
glass.6
Mesoporous nanoparticles are made using a micellar solution where the silica 
precursor condenses around the micelles. This creates a greater surface area and more 
silanols for further surface modification. The mesoporous structure allows for a greater 
accessibility to organic functionalities via the pores. Mesoporous silica nanoparticles
7 8have found applications in drug delivery and imaging because they are able to trap drug 
molecules, or imaging species, in their porous channels. Since silica nanoparticles often 
need to incorporate organic functionalities to make them useful, it would be beneficial to
54
55
synthesize silica nanoparticles that are made solely from the organosilane that provides 
the desired functionality.
Organically modified silica (ORMOSIL) nanoparticles are relatively new to the 
field of silica chemistry. These particles are synthesized by the hydrolysis and 
condensation of an organosilane in the absence of a tetraalkoxy silane. The advantage 
that an ORMOSIL nanoparticle has over a solid modified silica nanoparticle is a greater 
number of organic functionalities throughout its body. The organic functionalities are 
also more accessible because the silica matrix is distorted by the loss of a silicon-oxygen 
bond and steric effects, which create a degree of porosity.9 As with traditional silica 
nanoparticles, increasing the surface area of the ORMOSIL nanoparticles is thought to 
increase the number and accessibility of the organic functionalities.
ORMOSILs synthesized with vinyl-containing silanes are of interest because the 
vinyl groups can be modified to contain boric acids through hydroboration chemistry.9 As 
discussed in Chapter 1, nanoparticles that contain large amounts of boron have the 
potential to be effective boron neutron capture therapy (BNCT) agents. Additionally, the 
silica matrix provides a modifiable structure to which additional silanes can be attached.
This chapter describes two new synthetic methodologies for preparing large 
surface area vinyl ORMOSIL structures. These methodologies use micellar solutions to 
create mesoporous and surface-rough structures. Additionally, organic transformations 
are performed for the vinyl groups and the results are compared to "solid" vinyl 
ORMOSIL particles to determine the extent of vinyl modification and to create a boron 
carrier that can be potentially used in BNCT.
3.2 Experimental Section
3.2.1 Materials
Vinyltrimethoxy silane (VTMS, Gelest Inc.), Hexadecyltrimethylammonium 
bromide (CTAB, 99.0%, Sigma-Aldrich), Mesitylene (97%, 1,3,5-Trimethylbenzene, 
TMB, Sigma-Aldrich), Ethylene glycol (EG, Macron Chemicals), Ammonium hydroxide 
(28-30%, Sigma-Aldrich), 1 M Borane tetrahydrofuran (BH3THF, Sigma-Aldrich), 
Bromine (Br2, Sigma-Alrich), and Potassium permanganate (KMnO4, 99%, Sigma- 
Aldrich).
3.2.2 Instruments
Transmission electron microscopy (TEM, FEI Techna G2 T-12), Infrared 
spectroscopy (IR, Bruker Tensor 37), Nitrogen adsorption-desorption (BET analysis, 
Micrometrics ASAP 2020), and Thermogravimetric analysis (TGA, Instruments 2950 
Thermogravimetric Analyzer).
3.2.3 Mesoporous vinyl silica nanoparticle synthesis
A solution consisting of 0.5868 g CTAB, 90 mL MilliQ water, 43 mL ethanol, 15 
mL EG, and 3.6mL 25% NH4OH is stirred rapidly in a 250 mL round bottom flask at 70 
°C for 25 minutes. 0.690 mL of VTMS is then added to the solution and stirred for 72 
hours. The particles are collected by centrifugation and washed 3 times with ethanol. The 
particles are then added to a 100 mL round bottom flask containing 30 mL of a 1 M HCl 
ethanolic solution and heated at 80 °C for 12 hours to remove the CTAB. The particles 
are collected and then washed 3 times with ethanol.
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3.2.4 Surface-rough vinyl silica nanoparticle synthesis
A solution consisting of 0.5868 g CTAB, 0.66 mL TMB (2.95:1 TMB:CTAB),
90 mL MilliQ water, 43 mL ethanol, 15 mL EG, and 3.6mL 25% NH4OH is stirred 
rapidly in a 250 mL round bottom flask at 70 °C for 25 minutes. 0.690 mL of VTMS is 
then added to the solution and allowed to stir for 72 hours. The particles are then 
collected by centrifugation and washed 3 times with ethanol. The particles are then added 
to a 100 mL round bottom flask containing 30 mL of 1 M HCl ethanolic solution and 
heated at 80 °C to remove the CTAB. The particles are collected and then washed 3 times 
with ethanol.
3.2.5 Bromination of vinyl silica particles
0.1 g of the vinyl silica nanoparticles (vSNPs, 1.25 mmol) are placed in a 
scintillation vial containing 10 mL of dichloromethane and sonicated until the particles 
are dispersed throughout the solution. Three equivalents of bromine (0.19 mL, 3.75 
mmol) are added to the solution and then briefly sonicated. The solution is allowed to sit 
overnight to ensure complete reaction of the bromine (Scheme 3.1). The particles are 




Scheme 3.1: Representation of bromination and hydroboration of vSNPs.
3.2.6 Hydroboration of vinyl silica particles
0.1 g of the vSNPs is placed in a 25 mL round bottom flask. An excess of 1 M 
BH3THF (5 mL) and 6 mL of THF is added to the flask and stirred under nitrogen. After
3 hours, the flask is sonicated to disperse the particles and then stirred again overnight. 
The particles are then washed with THF 3 times to remove excess BH3THF, washed with 
a 9:1 ethanol-water mixture followed by sonication in MilliQ water to complete the 
conversion to boric acids, and then washed twice with MilliQ water (Scheme 3.1).
3.2.7 Potassium permanganate oxidation of vinyl silica particles
0.1 g of vSNPs are dispersed in 10 mL of ethanol. The solution is transferred to a
25 mL round bottom flask and stirred. 2 mL of a 5% w/v KMnO4 solution is added 
dropwise to the flask. The solution is stirred for 24 hours then collected via centrifugation 
and washed twice with ethanol. Concentrated H2SO4 and water is added to the brown 
precipitate and allowed to react for 3 hours or until the brown color disappears. The 
solution is then centrifuged to collect the white particles and washed once with dilute 
H2SO4 then 3 times with water.
3.3 Results and Discussion
3.3.1 Synthesis of vinyl silica nanoparticles
Presently, there are a few organosilane precursors that can form ORMOSIL 
nanoparticles.10 The vinyltrimethoxy silane (VTMS) precursor is one organosilane that 
not only forms ORMOSIL nanoparticles but can also provide a reactive organic group 
susceptible to bromination, hydroboration, hydroxylation, and oxidation. The other
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advantage to using VTMS is that it can undergo hydrolysis and condensation using the
simple Stober method.
Solid vinyl silica nanoparticles (svSNPs) were initially made to act as a baseline
for surface area comparisons. These particles were made using the same synthetic
procedure as mesoporous vinyl silica nanoparticles (mvSNPs), described below, except
that CTAB was not used. These particles are large in diameter (592 ± 18 nm) and non-
porous (Figure 3.1). Nitrogen absorption-desorption isotherm analysis on the svSNPs
2 1gave a BET surface area of 8.48 m g- . It should also be noted that the svSNPs absorb
3 1little nitrogen (~ 13 cm g- STP) and exhibit a type II isotherm (Figure 3.2), which is 
indicative of nonporous materials (Figure 3.3a).11
Factors such as ethylene glycol and the concentration of water and ethanol play an 
important role in the formation of mesoporous vinyl silica nanoparticle (mvSNP). The 
purpose of ethylene glycol is to provide high viscosity to the solution, which creates more 
silica nuclei for particle formation, and helps control the particle size and uniformity.
Figure 3.1: TEM image of svSNPs.
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Figure 3.2: Nitrogen adsorption-desorption isotherm of svSNPs.
Relative pressure
Figure 3.3: Representations of adsorption-desorption isotherms and hysteresis loops. 
a) Types of isotherms (type IV and type V are considered isotherms for mesoporous 
materials) b) Types of hysteresis loops.11
Several factors inhibit the mvSNP formation. When VTMS is added to a micellar CTAB 
solution that contains only water or ethanol, or if the ethanol:water ratio is lower than 
described in the procedure, the solution does not turn opaque, indicating that particles are 
not formed. The reaction can also result in a gel network when the concentration of 
ethanol is increased, when it is added after VTMS, or if the reaction time is less than 72 
hours (Figure 3.4a). If the solution temperature falls below 50 °C, the loss of porosity is 
observed (Figure 3.4b). It should be noted that the mvSNP synthetic method has a lower 
yield than the respective yield of svSNPs.
Distinct porous spherical structures were observed by TEM for the mvSNPs with 
an average particle size of 137 ± 8 nm (Figure 3.5a-b). These pores appear to have 
different sizes and are randomly distributed throughout the ORMOSIL body. The pore 
size variations may be caused by some of the hydrophobic VTMS precursor entering the 
hydrophobic micelle core and causing the micelle to swell. This may also be the 
explanation for the low product yield, especially if the pores are interconnecting during 
synthesis. An example of the mvSNPs nitrogen sorption isotherm is shown in Figure
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Figure 3.4: TEM images of a) Vinyl gel network produced b) nonporous 
particles observed below 50 °C.
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Figure 3.5: TEM images of mvSNPs synthesized at 70°C.
3.6a. This isotherm has an expected large nitrogen absorption (~260 cm g- STP) and 
appears to be type II (Figure 3.3a). However, it has an H1 hysteresis loop (Figure 3.3b) 
between 0.92 to 1 P/Po, indicating mesoporosity, and therefore, it is probably a type IV 
without the noticeable plateau, which is not uncommon for mesoporous materials.13,14
Although the large nitrogen absorption and hysteresis loop are indicative of a 
mesoporous material, the pore diameter measurement has a wide distribution of sizes 
from the 2 nm to 300 nm. This broad size range can be explained by a combination of 
micropores (< 2 nm), mesopores (2- 50 nm), some of which may be connected, and voids 
created by particle aggregation. Figure 3.6b shows the pore size distribution up to 50 nm 
to emphasize the periodic pore size maxima from 2 nm to ~ 30 nm (2, 7, 12, 18, and 23 
nm) demonstrating that the mesopores are not uniform in size. According to BJH 
calculations, the mvSNP samples have the average pore sizes between 36.8 and 50.4 nm, 
which roughly corresponds to the large pore sizes observed by TEM and the highest pore
3 1size from Figure 3.6b, and a pore volume of 0.32 cm g- . For comparison, svSNPs have
a "pore volume" of 0.02 cm g. Additionally, BET analysis of the mvSNP samples gave
2 1surface areas that lie between 30.32 and 43.96 m g- , which means that these particles 
have a surface area 3.5 to 5 times larger than svSNPs. This surface area is lower than that 
expected based on other large pore particles.14 This is likely due to the mvSNPs pore 
density being lower than that of typical mesoporous particles.
We expected that when the swelling agent TMB is added to the micellar CTAB 
solution prior to VTMS condensation, the VTMS particles will possess larger pores than 
the mvSNPs described above. However, this was not the case. When the product of this 








Figure 3.6: Nitrogen adsorption-desorption analysis of mvSNPs. a)Nitrogen 
adsorption-desorption isotherm of mvSNPs. b) Pore size distribution of 
mvSNPs between 0 and 50 nm.
size of 97 ± 6 nm (Figure 3.7a-b). This structure may be due to VTMS not being able to 
condense fully around the swollen micelles. However, the yield of the surface-rough 
particles was higher compared to mvSNPs, which is likely caused by TMB replacing 
some of the VTMS in the micelles, or causing the micelles to be "leaky" allowing for 
VTMS to enter and exit. The isotherm of these surface-rough vinyl silica nanoparticles
• * 3 1(rvSNPs), as with the mvSNPs, has a larger nitrogen adsorption (~450 cm g- ) than that 
of svSNPs. The main difference between the rvSNPs and mvSNP nitrogen sorption
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Figure 3.7: TEM images of rvSNPs.
isotherms is that the rvSNP's hysteresis does not have a "loop" like that of the mvSNPs 
(Figure 3.8). This implies that they contain porous areas that do not allow nitrogen to 
exit. According to BJH calculations, these rvSNPs have pores that are smaller than those
3 1
of the mvSNPs (18.5 nm) with volumes of 0.65 cm g- . This observation is likely due to 
the cavities created by the rough surface. If there were "through-and-through" pores of 
this calculated size, they would be visible by TEM. Even though there may be a degree of 
porosity, these vinyl silica particles have an obvious rough surface. These rvSNPs have a
P/Po
Figure 3.8: Nitrogen adsorption-desorption isotherm of rvSNPs.
BET surface area of 278.70 m g- , which is much larger than the surface area of either 
the mvSNPs or the svSNPs.
3.3.2 Bromination of vinyl silica nanoparticles
Bromination was performed first because Br2 reacts readily with alkene groups. 
We expected that brominating the vinyl particles will allow us to determine the extent of 
vinyl accessibility. The treatment of the vinyl particles with bromine produced an off- 
white colored powder. When brominated particles were examined using IR, a loss of the 
vinyl stretch at 960 cm-1 and a diminishment of the 1602 cm-1 stretch were observed. This 
suggests that the alkenes have indeed reacted. The small bands appearing at the 875 and 








Figure 3.9: IR spectra of vinyl (black), brominated vinyl (red), oxidized vinyl 
(green), and hydroborated vinyl (blue) nanoparticles.
TGA gave information about the extent of vinyl conversion via bromination. 
Brominated svSNP, rvSNPs, and mvSNPs exhibit similar weight losses of ~60%. This is 
much greater than the weight loss observed for the “solid” vinyl particles (~9%) (Figure 
3.10-3.12). Despite their surface areas which implies the amount of vinyl functionalities 
that are accessible, the vinyl nanoparticles have similar mole conversion percentages of 
~85% (Eq. 3.1-3.3). This result supports the idea of inherent ORMOSIL porosity and 
implies that these particles, with the exception of their surface areas, are not very 
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Figure 3.11: TGA weight losses of rvSNPs (black) and brominated rvSNPs 
(red).
Figure 3.12: TGA weight losses of mvSNPs (black) and brominated 
mvSNPs (red).
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p • g • 7i • r(Cm) • %Wi0SSvSNp mol vinyl 
100 • MWvinyi particle
Eq. 3.1: Determining the moles vinyl per particle based on TGA data: p is the particle 
density in g-cm- (~1.35), r is the particle radius, MWvinyl is the molecular weight of 
vinyl, and %Wloss is the measured weight loss of the vSNPs according to TGA.
4
P ‘ ^  ‘ 71 ‘ r (cm ) ‘ (% W lo ssv N P + x  — % W lo ssv N p )  mol X 
100 • MWX particle
Eq. 3.2: Determining the moles of bromine or boric acid in reacted vinyl particles: p is 
the particle density in g-cm- (~1.35), r is the particle radius, MWX is the molecular 
weight of bromine or boric acid, and %Wloss is the measured weight loss of the 
nanoparticle according to TGA.
mol X mol vinyl
--------— ---------- -— x 100 = mol % conversion
particle particle
Eq. 3.3: Determining the percentage of vinyls reacted during bromination or 
hydroboration.
3.3.3 Hydroboration of vinyl silica nanoparticles
Since one of the desired uses for these particles is to act as a boron carrier for 
BNCT, determining the amount of boron that each particle can carry is important. 
Initially, IR spectroscopy was used to determine if hydroboration has taken place. 
According to the IR spectrum (Figure 3.10), the vinyl nanoparticles have a Si-C stretch 
around 1410 cm-1 which broadens after hydroboration due to the presence of B-O 
vibrations. There is a band at 770 cm-1 representative of O-B-O and/or B-C stretches. The 
broad band at 3500 cm-1 is indicative of the presence of hydroxyl groups created when 
borohydride is converted into boric acid. Additionally, there is a new band at 1712 cm-1, 
which is characteristic of a C-B-C stretch. All of this indicates that vinyl groups were 
indeed converted to boric acid inside the vinyl nanoparticles. The hydroborated particles
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were placed into a hexane water mixture. While the vinyl particles remain in hexane, the 
hydroborated particles disperse into the aqueous layer (Figure 3.13).
Since other svSNPs have been synthesized and hydroborated,9 we used them to 
compare the extent of hydroboration for our vinyl nanoparticles and the amount of boron 
they carry per unit volume. Calculating the number of boron atoms per unit volume was 
used to avoid the confusion presented by the different particle sizes for the different vinyl 
particles. For svSNPs, TGA results show a weight loss of ~9.7% and the hydroborated 
svSNPs have a weight loss of ~19.0% (Figure 3.14). Using Eq. 3.4, the number of boron
21 3 8atoms per volume was calculated to be 1.69 x 10 B cm- (1.8 x 10 B per particle). The 
mole conversion of the svSNP's vinyl groups by hydroboration was determined to be 
~58%.
mol B(OH)2 1 mol B 
particle 1 mol B(OH)2 A #B
4 3 cm32 # 71 • l(cm)
Eq. 3.4: Determining the number of borons atoms per unit volume in each 
vSNP.
Figure 3.13: The hydrophobic mvSNPs are located in the hexane 
layer of the vial (Left). The hydroborated mvSNPs are located in 
the aqueous layer (Right).
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Figure 3.14: TGA weight losses of svSNPs (black) and hydroborated svSNPs 
(blue).
The rvSNPs showed a weight loss of ~9.3% and, after hydroboration, a weight 
loss of ~17.9% (Figure 3.15). This corresponds to the conversion of vinyl groups and
21 3boron atoms per volume similar to those of svSNPs, 55.7% and 1.56 x 10 B cm" (7.2 
x105 B per particle), respectively. Although the rvSNPs have a larger surface area, and 
presumably a greater number of surface vinyl groups than the svSNPs, the difference was 
negated because of the inherent porosity of svSNPs. The mvSNPs show an improvement 
to the hydroboration of the vinyl groups. A vinyl weight loss of ~8.4% along with a
21boronated weight loss of ~20.9% were observed (Figure 3.16). This gives a 2.3 x 10 
B cm -3 (3.1 x 106 B per particle) and a mole conversion of ~89.8% for vinyl groups, 
which is about 1.5 times greater than that for svSNPs or rvSNPs. This increase is most 
likely caused by the larger pores creating better access to the core vinyl functionalities.
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Figure 3.15: TGA weight losses of rvSNPs (black) and hydroborated rvSNPs 
(blue).
Temperature (°C)
Figure 3.16: TGA weight losses of mvSNPs (black) and hydroborated mvSNPs 
(blue).
3.3.4 Oxidation of vinyl nanoparticles
The data for vinyl oxidation is not complete, but there are some positive 
preliminary results for a svSNP oxidation based on IR (Figure 3.9) and TGA analysis 
(Figure 3.17). The IR spectrum shows little loss of C-H stretches as is seen with 
bromination and hydroboration, but the broad peak appearing at 3400 cm-1 representing 
O-H stretching indicates the oxidation of the alkene. Additionally, a small peak appears 
between the doublet at 1000-1200 cm-1 that may represent a C-O stretch (~1100 cm-1). 
Since there is no peak at 1700 cm-1, this IR spectrum indicates the conversion of the 
alkene into a diol instead of a carboxylic acid. It should be noted that there is a peak 
between 800 and 900 cm-1 that is probably caused by a S-O stretch from sulfuric acid 
contamination during oxidation.
When these oxidized svSNPs are measured with TGA, a weight loss of ~14%, 
between 200 and 800 °C is observed (Figure 3.17) indicating that the vinyl has been
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Figure 3.17: TGA analysis of oxidized svSNPs.
converted into a heavier organic compound. Assuming that the vinyl is being converted 
to a diol, a vinyl conversion of ~20% is calculated. The low percent of conversion may 
explain why IR peaks attributed to alkenes are still observed. The next process will be to 
determine the extent of vinyl oxidation for mvSNPs. These results will be used to 
compare the vinyl conversions of the svSNPs and mvSNPs to determine if the mvSNPs 
demonstrate a greater conversion of vinyl groups, as observed with the hydroboration 
data.
3.4 Conclusions
The syntheses of two new types of large surface area vinyl ORMOSIL 
nanoparticles have been presented. First, we used CTAB to create a micellar solution, 
producing large pore mesoporous vinyl particles. Secondly, we prepared surface-rough 
rough vinyl particles by adding the swelling agent TMB to the micellar solution. These 
particles may have an increased number of surface vinyl groups that could prove useful in 
making hydrophobic surfaces. Additionally, we demonstrated that vinyl ORMOSIL 
nanoparticles, specifically the mesoporous ones, could become excellent carriers for large 
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CHAPTER 4
SYNTHESIS OF SILICA SHELL/BORON CORE (B@SiO2) 
NANOPARTICLES
4.1 Introduction
In the United States alone there are about eleven million people with some form 
of cancer.1 Since the 1970s, the United States, through the National Cancer Institute 
(NCI), has put more than two hundred billion dollars into finding treatments and cures for 
cancer. Presently, treatments are limited to chemotherapy, surgery, radiation therapy, 
and interferon therapy. The problem with current methods is that none are localized to the 
tumor itself; even surgery requires damaging healthy tissue. This reduces their 
effectiveness and increases treatment complications. In 1936, George Locher proposed as 
a possible solution using boron as a localized cancer therapeutic. His idea is now known 
as boron neutron capture therapy (BNCT).3
Neutron capture therapy is based on the adsorption of slow neutrons in the nuclei 
of a nonradioactive isotope located inside, or adjacent to, the tumor cell. The adsorption 
of the neutrons leads to the release of radiation in the form of high linear energy transfer 
(LET) particles damaging the target cell. In addition to being nonradioactive, the isotope 
has to have a capture cross-section that is many times greater than that of elements 
typically found in tissues (Table 4.1) so that the neutrons are absorbed by the therapeutic 
isotope. A list of capture cross-sections can be seen in Table 4.2. 10B (BNCT) is the most
77
Table 4.1: Thermal Neutron Capture Cross-Section Values of Tissue 















H 0.332 10.00 P 0.18 1.16
C 0.0034 18.0 S 0.53 0.20
N 1.82 3.0 Cl 32.68 0.16
O 1.8 x 10-4 65.0 K 2.1 0.20
Na 0.43 0.11 Ca 0.4 2.01
Mg 0.053 0.04 Fe 2.57 0.01
Table 4.2: Capture Cross-Section Values of Various Nuclides 
for Thermal Neutrons.4
Nuclide Capture Cross- Nuclide Capture Cross-
Section (barns) Section (barns)
6Li 942 151Eu 5800
10B 3838 155Gd 61000
22Naa 32000 157Gd 255000
58Coa 1900 164Dy 1800
113Co 19800 184Os 3000
126 ja 6000 199Hg 2000
135Xea 2600000 230Paa 1500
148mPma 10600 235^ ja 580
149Sm 42000 241Pua 1010
a: Radioactive
popular isotope due to its low toxicity and chemistry that allows for easy incorporation
157into a variety of small and macromolecules. Gd (GdNCT) is the only other proposed 
potential neutron capture therapeutic because it is nonradioactive and it has the second 
highest capture cross-section of all elements. The challenges with GdNCT are that 
gadolinium is toxic and therefore must be tightly bound to the carrier, it has to be located 
closer to the nucleus to maximize LET damage, and the y rays it produces are not 
localized to the target cell.4
BNCT is the process in which boron-10 undergoes nuclear fission through an 
alpha decay pathway by absorbing a thermal neutron (0.025 eV). The fission reaction 
produces two high LET products, an alpha particle (1.47 MeV) and 7Li (0.84 MeV). The
3 5maximum range that these high LET products travel in tissue is 9 |im. , Since a typical 
human cell is 10-30 |im,6 the radiation is mainly localized to cells containing 10B, with 
some possible damage done to immediately adjacent cells.
Although localized treatment is important, there are two requirements that any 
boron compound must meet to be a plausible BNCT agent. First, the minimum amount of 
10B must be ~109 atoms per cell to provide a greater chance for neutron capture, and 
second, the tumor-to-normal tissue and tumor-to-blood boron concentration must be 
greater than 3:1, so as to localize the BNCT reaction to the tumor without doing
3 7 10irreparable damage to the normal tissues. , -
There are two boron compounds that have been clinically studied as BNCT 
agents, mercapto-undecahydro-closo-dodecaborate (BSH) and p-boronophenylalanine
3 1112(BPA). , , In animal testing studies, BSH has a tumor-to-blood ratio of 1.3:1, which is 
much less than the required ratio. It has been suggested that the tumor-to-tissue ratio is 
more important than the tumor-to-blood ratio; therefore, if that ratio is increased, the 
BSH is still a good treatment candidate. BPA meets both requirements. It is, however, 
selective only to gliomas and melanomas. According to clinical studies of BPA, a
13minimum dosage of 250 mg/kg body weight is needed to be effective, because only 1 
out of every 5 BPA molecules (20% 10B) could undergo neutron capture. Besides BPA 
and BSH, boronporphyrins,14,15 amino acids,16 polyhedral boranes,17,18 boronated anti-
19 20 21epidermal growth factor receptor, DNA-binding agents, , and monoclonal
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antibodies have been proposed as alternative boron delivery agents. Presently, 
increasing the 10B capacity to improve the chance of neutron capture has become a focus 
for modern BNCT agent preparation.
Recently, boron nanoparticle hybrids (e.g. boron carbide) have been suggested as 
possible boron neutron capture therapy (BNCT) agents because of their high boron
23content. Elemental boron nanoparticles (BNPs) also have a high calculated boron
7 24content (~10 boron atoms per 50 nm particle). Even though the studies of elemental
25boron nanoparticles focused on their fuel applications, if the particles were made water- 
dispersible and thus could be used in biological media, they would also have potential as 
a boron neutron capture therapeutic. How to make them water-dispersible is a problem 
that may be solved using silica coating. As discussed in Chapter 1, silica is highly 
advantageous as an inorganic nanoparticle carrier for physiological uses, because it 
provides a modifiable, hydrophilic shell.
4.2 Experimental Section
4.2.1 Materials
Elemental boron powder (95-97%, Sigma-Aldrich), Undecenoic acid (UND 
acid, 95%, Sigma-Aldrich), Triethoxy silane (95%, Sigma-Aldrich), Tetraethoxy silane 
(TEOS, 99.999+%, Alfa Aesar), Ammonium hydroxide (28-30%, Sigma-Aldrich), 3- 
aminopropyltriethoxy silane (APTES, 98%, Sigma-Aldrich), Dansyl chloride (99%, 





Transmission electron microscopy (TEM, FEI Techna G2 T-12), UV/Vis 
spectrophotometer (Mikropack DH-2000 UV-Vis-NIR), Scanning transmission electron 
microscopy with energy dispersive x-ray spectroscopy (STEM-EDS, FEI Titan 80-300).
4.2.3 Air stable boron nanoparticle preparation
The BNPs are made26,27 using 2 g of microscale elemental boron powder that is 
ground in a Retsch PM400 planetary mill with tungsten carbide in a milling jar at an 80:1 
charge ratio (ball and powder ratio). To protect boron surfaces from oxidation, 1 mL of 
undecenoic acid (UND acid) is added to the boron and 15mL hexane mixture prior to 
milling. The resultant particles are washed 3 times in hexane to remove excess fatty acid 
and redispersed in 200 proof ethanol. TEM is used to analyze morphology and size 
distribution of BNPs.
4.2.4 Hydrosilylation reaction
Triethoxy silane is added to the surface of the UND-modified BNPs by 
redispersing 0.0798 g of dry BNPs in dry acetonitrile (15 mL). 1mL of triethoxy silane is 
added to the reaction flask and stirred for 24 hours in the presence of a Speier's catalyst, 
H2PtCl6 6H2O (7.0 mg). The particles are then washed twice with acetonitrile and 3 times 
with ethanol to remove any excess triethoxy silane. The particles (0.049 g) are 
redispersed in ethanol (13 mL).
4.2.5 Coating of BNPs with silica
28The Stober method is implemented to complete the silica shell formation around 
the BNPs. Ammonium hydroxide (0.116 mL), tetraethoxy silane (0.25 mL, TEOS),
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MilliQ water (0.791 mL), and absolute ethanol (3 mL) are added to 2 mL of the triethoxy 
silane BNP solution and stirred for 24 hours. The particles are washed with ethanol 5 
times to remove free TEOS and pure silica nanoparticles, leaving a black powder. If a 
white silica layer persists, the centrifuged particles are left in ethanol overnight to allow 
the pure silica nanoparticles to slowly disperse in the solution. This is then followed by 
the removal of the supernatant so that only the black silica coated BNPs are present. Size 
and morphology are observed by TEM. The particles are also added to water to determine 
if they are water-dispersible.
4.2.6 APTES modification
The silica-coated BNPs (B@SiO2 NPs) are dried and redispersed in dry 
acetonitrile (5 mL). 2% v/v of 3-aminopropyltriethoxy silane (APTES) is added to the 
solution and stirred for 17 hours. The APTES solution is then washed 5 times with dry 
acetonitrile, to remove any excess APTES, and redispersed in ethanol.
4.2.7 Fluorescent tag addition
Dansyl chloride is used as the fluorescent tag, because it reacts quickly with 
primary amines. 4 mg of dansyl chloride, in 5 mL dry acetonitrile, is added to the 
B@SiO2 NPs and the APTES modified B@SiO2 NPs. The particles are washed with 
acetonitrile until the supernatant no longer fluoresces. A UV lamp is used to observe 
fluorescence.
4.2.8 Curcumin study
The curcumin study requires four solutions to be made prior to mixing with 
boron, 1) an acetic acid buffer, 2) sulfuric-glacial acetic acid reagent, 3) curcumin, and 4)
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100 ppm boric acid stock solution. The solutions are prepared following the procedure
29described by Liu and Lee. 1 L of the acetic acid buffer is made by mixing 135 mL of 
glacial acetic acid with 180 g of ammonium acetate (Merck) in 90 mL of ethanol and 
diluted to 1 L with MilliQ water. The sulfuric-glacial acetic acid solution is made by 
mixing a 1:1 ratio by volume of concentrated sulfuric acid and glacial acetic acid to a 
total volume of at least 20 mL. The curcumin solution is made by taking 0.125 g of the 
curcumin powder and adding it to 100 mL glacial acetic acid. The boron stock solution 
(100 ppm) is prepared by dissolving 0.5717 g boric acid to a final volume of 1 L in 
MilliQ water. All solutions are kept in nalgene bottles to avoid boron contamination from 
glassware.
To obtain a standards curve, five boric acid solutions (1-5 ppm) are made from 
the 100 ppm stock solution. 500 |iL of each boric acid solution are taken and added to a 
50 mL nalgene bottle. Subsequently, 3 mL of acetic anhydride is added, to avoid water 
contamination that can interfere with curcumin, and let sit for 20 minutes. 3 mL of the 
curcumin solution and sulfuric acid/glacial acetic acid solution are added to the bottle and 
allowed to react for 70 minutes to ensure complete reaction. Then each solution is 
quenched with 20 mL of the acetic acid buffer to remove any of the interfering curcumin- 
proton complex and their absorbance is measure at 543 nm. The BNPs and B@SiO2 NPs 
curcumin tests are done in the same fashion.
Another calibration curve is made using a 1 M KOH in ethanol solution. The 
calibration procedure is done the same way, except 1 mL of acetic anhydride is replaced 
by 1 mL of the KOH solution. The boric acid standards are added to the KOH and let sit
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overnight before the test is performed. The B@SiO2 NPs are also placed in KOH, but 
prior to sitting overnight, they are sonicated for 8 hours.
4.3 Results and Discussion 
The BNPs made by the surfactant-assisted ball milling method in the presence of
27oleic acid are air stable,27 because the surface fatty acids prevent the oxidation to boron 
oxide (B2O3). However, the fatty acids cause them to be hydrophobic, preventing them 
from being used in biological applications. Coating BNPs with silica would make them 
hydrophilic and would also allow for easy surface modifications.
UND acid was chosen as the surfactant for the ball milling method, as opposed to
the original oleic acid ligand in the literature, 26,27 because it contains a terminal alkene
30 33group. The alkene can react with silanes through a hydrosilylation reaction. - By 
treatment with triethoxy silane, the surface of the BNPs acquires a layer of Si(OEt)3. It is
expected that the initial ethoxysilane layer will react with TEOS under the Stober
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Scheme 4.1: Coating fatty acid boron nanoparticles with silica.
Previously, we reported that PND-BNPs have a size distribution ranging from 11
24to 70 nm with the average size of 38 nm. After the treatment with triethoxy silane and 
TEOS, the resulting particles appear spherical, homogeneous in size (64 ± 3 nm), and 
distinctly separated as seen in TEM images (Figure 4.1a). This implies that a silica shell 
of 26 nm in thickness is forming around the BNPs. These particles are distinctly different 
from the amorphous BNPs (Figure 4.1b), but no core-shell structure is observed to 
indicate boron encapsulation. This is likely due to the lower density of boron compared to 
silica, which results in the electron beam penetrating higher to lower density 
nanoparticles. The absence of amorphous material and the presence of spherical particles 
suggest that boron is indeed encapsulated by silica. Because the core-shell structure 
cannot be imaged, a colorometric study and STEM-EDS were used to confirm their 
structure.
The molecules that can form complexes with boron and be measured 
spectrophotometrically are 1,1- dianthrimide,34 carmine,35 azomethine-H,36 and
37curcumin. Curcumin, often used to determine boron concentrations in water and soil, 
complexes with boron to form rosocyanine, which has an orange to red color. Figure 4.2 
shows the linear dependence of boron-curcumin complex absorbance on boron
38concentration at 543 nm. Curcumin can react with micron-sized boron powder; 
therefore, we expected that the BNPs will form a complex with curcumin, but the silica- 
coated BNPs will not because of their protective shell.
Because the weight added by silica is unknown but is expected to be small, BNP 
and B@SiO2 NP samples were prepared with equal concentrations (~3800 ppm) on the 
assumption that all sample mass is elemental boron. Even though the sample
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Figure 4.1: TEM images of a) Silica coated boron 
nanoparticles b) amorphous boron nanoparticles.
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Boric Acid Samples without KOH




Boric Acid 0 ppm 1 ppm 2 ppm 3 ppm 4 ppm 5 ppm 














Boric Acid 0 ppm 1 ppm 2 ppm 3 ppm 4 ppm 5 ppm 
Absorbance 0 0.29 0.55 0.68 0.94 1.18
Figure 4.2: Calibration curves for curcumin study.
concentration used was higher than the concentration of the standards, it was 
demonstrated that for micron-sized boron powder, curcumin will react with the surface
37only. This results in measured boron concentrations that are between 0.05-0.1 % of the
38total boron concentration. BNPs in curcumin have a much higher absorbance at 543 nm 
compared to B@SiO2 NPs (Table 4.3). This indicates that BNPs complex with the 
curcumin, despite the surface ligand, and that the silica shell is protecting the boron core
0 1 5 6
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Table 4.3: Absorbance Measurements of Boron Samples.
Absorbance Boron detected (ppm)
BNPs 1.383 5.91
B@SiO2 0.099 0.32
B@SiO2 in KOH 0.560 2.30
from curcumin. Since the B@SiO2 NPs did give a low absorbance, it is likely that some 
BNPs are not fully encapsulated, the silica shell is slightly porous, or some boric acid is 
present on the surface of B@SiO2 NPs.
If B@SiO2 NPs are indeed formed, dissolving the silica should expose the boron 
to the curcumin and a significantly larger absorbance should be observed. The two 
common reagents used to dissolve silica are hydrofluoric acid (HF) or sodium/potassium 
hydroxide (NaOH/KOH). We used HF first to dissolve the silica shell because of the 
expected high rate of its reaction with silica. However, when the resulting samples were 
studied, the absorbance was similar to that for the B@SiO2 NPs. This may be the result of 
HF forming fluoroborates, which are very volatile and may be released into the 
atmosphere during sample preparation, or, although fluoroborates are made, the curcumin 
could not chelate them because of the strong B-F bond.37 The use of KOH was more 
successful because the resulting boron particles reacted with curcumin and the presence 
of KOH had little to no effect on the calibration curve (Figure 4.2). After stirring the 
B@SiO2 NPs in KOH solution for 24 hours and performing the curcumin procedure, we 
observed a 6 fold increase in absorbance and therefore, in boron concentration (Table 
4.3), compared to that of untreated B@SiO2 NPs. Thus, this qualitatively confirms that 




Figure 4.3: B@SiO2 NPs in curcumin without KOH (left) and 
B@SiO2 NPs in curcumin after dissolving silica shell (right).
detected in B@SiO2 NPs (by a factor of ~2.5) after the silica shell is dissolved compared 
to that of the BNPs is likely due to the silica shell providing a more significant weight to 
the BNPs than initially assumed, resulting in a lower effective boron concentration.
The elemental analysis of the BNPs and B@SiO2 NPs was performed using 
STEM-EDS. For the BNPs, STEM-EDS spectrum exhibits an intense peak at 0.187 keV 
corresponding to boron atoms (Figure 4.4). The B@SiO2 NPs STEM-EDS spectrum 
exhibits a boron peak and also a peak at 1.75 keV, corresponding to silicon (Figure 4.5). 
This demonstrates that both silica and boron are present in the same particle. The 
elemental composition of the BNPs includes a large amount of boron outweighed only by 
oxygen (Table 4.4). When elemental analysis of the B@SiO2 NPs is performed, the 
weight ratio of silica to boron is calculated to be 1.05:1 (Table 4.5). This explains why 
the measured boron concentration of dissolved B@SiO2 NPs is about half that of the 
BNPs. The silica shell thickness can be calculated based on the determined weight ratio.
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Figure 4.4: STEM-EDS spectrum of boron nanoparticles.
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Figure 4.5: STEM-EDS spectrum of B@SiO2 NPs.
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Table 4.4: Elemental Analysis of Boron Nanoparticles.
Element Weight% Atomic% Compd% Formula
B K 17.84 24.09 57.45 B2O3
C K 10.50 12.76 38.46 CO2
Cu L 3.26 0.75 4.08 CuO
O 68.40 62.40
Totals 100.00
Table 4.5: Elemental Analysis of B@SiC>2 NPs.
Element Weight% Atomic% Compd% Formula
B K 0.83 1.13 2.68 B2O3
C K 26.32 32.18 96.44 CO2
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Eq. 4.1: Determining silica shell thickness: p is the density of the particle, 
rSio2 is the unknown thickness of the silica shell, rBNP is the determined 
radius of the boron nanoparticle, and WSiO2 and WB are the EDS weight 
percentages of silica and boron.
This is done by using Eq. 2.1 and assuming the densities of the BNPs and the B@SiO2 
NPs are similar. The silica shell thickness is calculated to be 10 nm, which is not 
significantly different from the 26 nm value calculated from the average particle sizes 
of B@SiO2 NPs and BNPs. It should be noted that the absolute amount of boron detected 
in the B@SiO2 NPs sample is much smaller than that observed for the BNPs sample. This 
can be attributed to the presence of the silica shell, but it more likely results from the 
presence of adventitious carbon.
To make B@SiO2 NPs more suitable for BNCT, the silica shell was modified 
with APTES to provide primary amines to the surface. With primary amine 
functionalities, targeting ligands and fluorophores can be attached to the surface of the 
B@SiO2 NPs. Treating these aminated particles with an amine-reactive fluorophore is an 
additional method to confirm the formation of the silica shell. Thus, dansyl chloride was 
used with APTES-modified B@SiO2 NPs because it reacts rapidly with primary amines 
and forms a fluorescent species. When dansyl chloride was added to the APTES- 
modified particles, a blue-green fluorescence was observed, which was absent for 
unmodified B@SiO2 NPs treated with dansyl chloride (Figure 4.6). This qualitatively 
demonstrated that the B@SiO2 NPs can be modified with primary amines.
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Figure 4.6: Dansylation of APTES modified B@SiO2 NPs.
Boron nanoparticles contain a large amount of boron compared to most other 
BNCT agents. The challenge in using them therapeutically is to make boron 
nanoparticles water-dispersible. We demonstrated that boron nanoparticles can be 
encapsulated in a silica shell to make water-dispersible boron/silica core-shell 
nanoparticles. Silica encapsulates the boron to produce spherical nanoparticles with the 
average 64 nm diameter and 3 nm dispersity, and with the silica shell thickness estimated 
to be between 10 and 26 nm. The presence of boron was confirmed by the curcumin 
complexation studies and STEM-EDS analysis. Furthermore, we were able to modify the 
silica shell surface with primary amines that allow for the attachment of a fluorophore 
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
5.1 Conclusions
Silica nanoparticles can act as carriers for fluorophores, organic functionalities, 
and other nanoparticles. Silica nanoparticles provide an inert, hydrophilic structure that 
does not react with their cargo. Organosilanes impart organic functionalities to the 
surface of the silica nanoparticles, making the particles multifunctional. This work 
demonstrated different synthetic methodologies for the production of internally 
functionalized silica nanoparticle.
To demonstrate the utility of internally functional silica particles, we developed a 
synthetic strategy to produce metal-chelating mesoporous nanoparticles using co­
condensation of TEOS with an organosilane (SiDETA) which is presented. This provides 
a porous network with the organosilane included throughout the mesoporous nanoparticle 
body. The DETA functionality can be modified with bromoacetic acid to produce the 
EDTA analog DTTA, which imparts the metal-chelating functionality to mesoporous 
nanoparticles.
Gadolinium was chelated by the mesoporous DTTA-containing nanoparticles that 
may find applications as MRI contrast agents. The amount of gadolinium chelated by 
theses nanoparticles is 46500 Gd atoms per particle. Because all gadolinium atoms are 
chelated by surface DTTA groups, they are accessible to water, which is the main
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requirement for MRI. Additionally, gadolinium has been proposed as a neutron capture 
therapeutic. Thus, our gadolinium-chelating nanoparticles combine imaging and 
therapeutic modalities.
To increase the accessibility of the functional groups inside the silica 
nanoparticles, we synthesized, for the first time, mesoporous and surface-rough 
organically modified silica (ORMOSIL) nanoparticles. The ORMOSILs are synthesized 
using vinyltrimethoxy silane in a micellar CTAB solution. The mesoporous vinyl 
nanoparticles synthesized in the micellar solution have larger surface areas than the solid 
vinyl particles. The surface-rough vinyl nanoparticles have a surface area larger than the 
solid vinyl and mesoporous vinyl particles. When brominated or hydroborated, however, 
the rvSNPs show no significant difference in the percentage vinyls converted when 
compared to reacted svSNPs.
The mesoporous vinyl nanoparticles have a smaller surface area than the surface- 
rough particles, but because of their additional pores, the extent of hydroboration is 
almost double that of the other ORMOSILs. This means that our mesoporous particles, 
on a per volume basis, carry more boron atoms than the solid or surface-rough particles. 
Both the mesoporous and surface-rough particles have excellent potential as a BNCT 
agents because of their boron loading and particle diameter.
To further increase the amount of boron atoms delivered to cancer cells for BNCT 
and to make biocompatible theranostic anticancer agents, we developed the synthesis of 
boron-core-silica-shell nanoparticles. We prepared these particles by forming the 
hydrophilic silica shell on the surface of suitably modified boron nanoparticles. These 
core-shell nanoparticles were characterized using STEM-EDS and curcumin titration (as
a colorimetric indicator). These characterization steps confirmed that boron has being 
encapsulated inside the silica shell. Additionally, the silica shell was modified with 3- 
aminopropyltriethoxysilane to place primary amines on the silica surface. A variety of 
species (fluorophores, targeting ligands) can then be attached to the surface and give the 
core-shell particle imaging and therapeutic properties.
5.2 Future Directions 
Even though silica nanoparticles have been continuously studied since the 1960s, 
they are still being improved and developed for a variety of applications. The new field of 
ORMOSIL chemistry and its benefits provide for expansion of tradition silica chemistry.
Because the silica nanoparticles mentioned throughout this thesis have been 
suggested as potential NCT agents, their cytotoxic effects must be studied if they are to 
be used in biological applications. In addition to conducting cytotoxic studies, work 
needs to be done to determine the location of the particles with respect to the cells, to 
predict the effect of the irradiative damage. If the nanoparticles have little to no toxicity 
against normal cells, then ligands that targets tumor cells (gliomas have been the focus of 
BNCT agents) should be attached to the surface to determine if the nanoparticles meet the 
3:1 tumor-to-normal cell requirement of BNCT. Lastly, the neutron capture of the 
particles should be studied to determine if these particles can undergo BNCT within the 
silica particle body, and to discover if they have significant cytotoxic effect when 
activated by the neutrons.1
Relaxivity measurements of the gadolinium-carrying nanoparticles should be 
performed to determine their suitability for use as MRI contrasting agents. It would also 
be beneficial to determine if the mesoporous nanoparticles carrying gadolinium have any
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toxicity to the body, perhaps by gadolinium being released from the DTTA complexes. 
This is unlikely based on the evidence of other DTTA-Gd chelators, but is still a 
potential issue that should be addressed with any newly developed particle carrying toxic 
metals. Another interesting study would be to determine through animal testing if the 
particles are excreted from the body.
Metal-chelating nanoparticles might also be beneficial as X-ray computed 
tomography (CT) agents. This would involve chelating bismuth as the contrast agent. It 
is known that bismuth can be chelated by EDTA and EDTA analogs, so the difficulty 
would be in determining the particle dosage requirement that is needed for imaging. 
Additionally, bismuth-212 has potential in targeted alpha therapy (TAT) of cancer, 4 so 
once again the metal-chelating particle may have a theranostic application.
Since novel vinyl ORMOSIL nanoparticles have been developed, the next step is 
to synthesize additional mesoporous or surface-rough structures from different 
organosilanes. Additionally, if two organosilanes were co-condensed,5 it would create a 
mesoporous or surface-rough structure with two organic functionalities without the need 
for postmodification. For example, it has been suggested that boron and gadolinium 
might work well together for NCT. This could be accomplished by co-condensation of 
VTMS with SiDTTA, since that would provide two organic functionalities, one (DTTA) 
that can chelate gadolinium and the other (vinyl) that can be hydroborated to incorporate 
boron atoms.
As was discussed briefly in Chapter 3, the rvSNPs have a potential in creating 
water-repelling glass. This is due to the large surface area and high vinyl density on the
99
surface. To further explore this application, water contact angle should be determined to 
see if the rvSNPs do in fact have a superhydrophobic surface.6
The development of these silica nanoparticles for medical usage is going to be a 
lengthy process. Even though potential applications of the particles have been discussed, 
they may be medically useless because of potential biological complications. 
Nonetheless, the synthetic strategies we developed will allow us to consider alternative 
applications for silica nanoparticles.
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